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ABSTRACT 
Insulin, secreted by pancreatic β-cells, has a preeminent role in regulating 
metabolism in virtually all tissues. Highly conserved through evolution, intracellular 
insulin signaling pathways are tightly regulated, but have been recently challenged 
by drastic changes in our lifestyles. The following impairment in insulin response, 
termed insulin resistance, is an important feature of type 2 diabetes, a condition that 
has reached the proportions of a worldwide epidemic. 
It is therefore important to gain a better understanding of how insulin resistance 
develops, what the interplay is between different tissues, and whether 
pharmacologically enhancing insulin sensitivity is possible. This thesis focuses on 
gathering novel information about how an inherited failure in insulin signaling 
(Study I), brain insulin signaling (Study II), and antidiabetic medicine dapagliflozin 
(Study III) can alter whole-body and tissue-specific insulin sensitivity. 
The studies were performed by using positron emission tomography (PET) scans 
with a glucose analogue tracer ([18F]-FDG) together with systemic (Studies I and III) 
and central hyperinsulinemia (Study II) to assess changes in tissue insulin-stimulated 
glucose uptake (GU). 
The results from Study I revealed that inherited impairment in skeletal muscle 
insulin sensitivity resulted in insulin resistance in all key metabolic organs even 
before the onset of T2D, while also establishing the role of [18F]-FDG-PET in 
determining the phenotype associated with a rare genetic variant. In Study II, it was 
demonstrated that brain insulin signaling induced by intranasal insulin does not have 
a significant effect on GU in peripheral tissues, but results in lower brain GU under 
mild systemic hyperinsulinemia. While dapagliflozin did not improve insulin 
sensitivity either (Study III), 8 weeks of treatment reduced liver fat content, as well 
as subcutaneous and visceral adipose tissue mass, in overweight T2D subjects. 
In conclusion, these studies elucidate how a genetic variant primarily impairing 
skeletal muscle insulin sensitivity, central response to hyperinsulinemia, and 
treatment with dapagliflozin can affect tissue-specific insulin sensitivity. 
KEYWORDS: Insulin sensitivity, glucose uptake, PET, intranasal insulin, 
dapagliflozin 
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TIIVISTELMÄ 
Haiman β-solujen erittämällä insuliinilla on merkittävä rooli aineenvaihdunnan 
säätelijänä lähes kaikissa kudoksissa. Solunsisäinen insuliinisignalointi on 
kehittynyt evoluutiossa varhain ja on tiukasti säädeltyä, eikä ole vielä onnistunut 
vastaamaan erittäin nopeaan muutokseen elämäntyylissämme. Tästä seuraava 
kudosten heikentynyt kyky reagoida insuliiniin, eli insuliiniresistenssi, voi johtaa 
tyypin 2 diabeteksen puhkeamiseen. 
Sen vuoksi on tärkeää ymmärtää paremmin miten insuliiniresistenssi syntyy, 
miten eri kudokset vaikuttavat siihen, ja voidaanko tilannetta parantaa 
lääkkeellisesti. Tämän väitöskirjan tavoitteena on tutkia miten perinnöllinen vika 
erityisesti lihaksen insuliinisignaloinnissa (osatyö I), keskushermoston säätely 
(osatyö II) ja diabeteslääke dapagliflotsiini (osatyö III) voivat vaikuttaa kudosten 
insuliiniherkkyyteen. 
Tutkimuksissa käytettiin positroniemissiotomorafia (PET) –kuvauksia yhdessä 
glukoosimerkkiaineen ([18F]-FDG) kanssa. Insuliiniherkkyyden mittaamiseksi 
kuvausten aikana tutkittaville annettiin insuliinia verenkiertoon (osatyöt I ja III) tai 
nenäsumutteena (osatyö II).  
Osatyössä I todettiin ensisijaisesti lihaksen insuliiniherkkyyttä alentavan 
geenivariantin aiheuttavan insuliiniresistenssiä laajasti myös muissa kudoksissa. 
Lisäksi tutkimuksella vahvistettiin [18F]-FDG-PET:n roolia harvinaisten 
geenivarianttien vaikutusten tutkimisessa. Osatyössä II todettiin, ettei nenä-
sumutteena annettu insuliini saanut aikaan merkittävää muutosta muiden kudosten 
glukoosiaineenvaihdunnassa, mutta aivojen glukoosinotto väheni merkittävästi 
sumutteen jälkeen. Myöskään dapagliflotsiini ei vaikuttanut merkitsevästi kudosten 
insuliiniherkkyyteen (osatyö III), mutta 8 viikon hoito vähensi maksan ja vartalon 
rasvan määrää ylipainoisilla tyypin 2 diabetesta sairastavilla tutkittavilla. 
Yhdessä nämä tutkimukset tuovat uutta tietoa siitä, miten lihaksen insuliini-
resistenssiä aiheuttava geenivariantti, aivojen vaste korkeaan insuliiniannokseen, 
sekä hoito dapagliflotsiinilla voivat vaikuttaa kudosten insuliiniherkkyyteen. 
AVAINSANAT: Insuliiniherkkyys, glukoosin soluunotto, PET, insuliininenäsu-
mute, dapagliflotsiini   
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Abbreviations 
[18F]-FDG 2-deoxy-2-[18F]fluoro-D-glucose 
Ac-CoA Acetyl coenzyme A 
Agrp/NPY Agouti-related protein/neuropeptide Y neurons 
AKT1, -2, -3 V-AKT murine thymoma viral oncogene homolog 1,2 and 3 (also 
PKBα, -β, -γ) 
ALT Alanine aminotransferase 
AST Aspartate transaminase 
AT Adipose tissue 
ATP Adenosine triphosphate 
BAT Brown adipose tissue 
BBB Blood-brain barrier 
CCK  Cholecystokinin 
CNS Central nervous system 
CT Computed tomography 
DAG  Diacylglycerol 
DPP-4 inhibitor Dipeptidyl peptidase 4 inhibitor 
EGP Endogenous glucose production 
FFA  Free fatty acid 
FGF21 Fibroblast growth factor 21 
FOXO  Transcriptional factor forkhead box O 
FUR Fractional uptake rate 
G6P  Glucose-6-phosphate 
GIP  Glucose-dependent insulinotropic peptide 
GIR Glucose infusion rate 
GLP-1 Glucagon-like peptide-1 
GLUT1, -2, -3, -4 Glucose transporter 1, 2, 3 and 4  
GSK3 Glycogen synthase kinase-3 
GU Glucose uptake 
HDL High-density lipoprotein 
HOMA-IR  Homeostatic model assessment for insulin resistance  
HU Hounsfield unit 
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IL-6 Interleukin-6 
INI Intranasal insulin 
IR Insulin receptor 
IRS Insulin receptor substrate 
i.c.v. Intracerebroventricular 
i.v. Intravenous 
LC Lumped constant 
LDL Low-density lipoprotein 
MBq Megabecquerel 
MCR Metabolic clearance rate 
MRI Magnetic resonance imaging 
mTORC1, -2 Mammalian target of rapamycin complex 1 and 2 
NAFLD Non-alcoholic fatty liver disease 
NT-proBNP N-terminal prohormone of brain natriuretic peptide 
OGTT Oral glucose tolerance test 
PDC  Pyruvate dehydrogenase complex 
PDFF% Proton density fat fraction 
PET Positron emission tomography 
PGC-1α  Peroxisome proliferator-activated receptor γ coactivator 1α 
PI3K Phosphatidylinositol 3-kinase 
PKBα, -β, -γ Protein kinase B α, β and γ (also AKT1, -2, -3) 
PKC Protein kinase C 
POMC/CART Pro-opiomelanocortin/cocaine- and amphetamine-regulated 
transcript neurons 
Rd Rate of disappearance 
SGLT2 Sodim-glucose cotransporter 2 
SNS Sympathetic nervous system 
T2D Type 2 diabetes 
TAG  Triacylglycerol 
TNFα  Tumor necrosis factor α 
WAT White adipose tissue 
VLDL Very low -density lipoprotein 
VOI Volume of interest 
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1 Introduction 
Insulin, produced by pancreatic β-cells in humans, plays a distinct role in promoting 
anabolic processes in the postprandial state and in regulating cell survival and growth 
in virtually all tissues. Insulin, insulin receptors (IRs), and the downstream pathways 
are highly conserved across species demonstrating early development during 
evolution (Saltiel & Kahn, 2001). This system has been challenged by the relatively 
recent changes in our lifestyles: constant availability of high-calorie and highly 
palatable foods, low physical activity, and the associated obesity all contribute to the 
impairment of insulin response in tissues, termed insulin resistance.  
The major effects of increased insulin secretion after a meal are enhanced 
glucose uptake (GU) and storing in skeletal muscle, promoted storing of excess 
glucose as glycogen and triacylglycerols (TAGs) in the liver while inhibiting hepatic 
endogenous glucose production (EGP), and improved storing and restricted release 
of fatty acids in adipose tissue (AT). These peripheral tissues, as well as the brain, 
all contribute to maintaining normal metabolic homeostasis, whereas, adversely, 
impaired insulin sensitivity in one tissue will eventually result in a deteriorated 
response to insulin in the whole body (Roden & Shulman, 2019). 
As insulin resistance is the major characteristic of type 2 diabetes (T2D)—a 
disease currently affecting over 400 million adults worldwide—and with the number 
of affected individuals rising steeply (International Diabetes Federation, 2019), it is 
of high priority to improve our understanding of the development of insulin 
resistance, tissue cross-talk in mediating insulin’s effects, and the possibilities for 
improving insulin sensitivity.  
This thesis targets these aspects by (I) describing the changes in tissue-specific 
insulin-stimulated GU caused by a rare genetic variant that predominantly affects 
skeletal muscle GU and glycogen synthesis; (II) investigating whether brain insulin 
exposure affects peripheral tissue GU under mild systemic hyperinsulinemia in 
healthy subjects; and (III) determining whether insulin resistance is alleviated in 
response to treatment with an antidiabetic medicine, sodium-glucose cotransporter 2 
(SGLT2) inhibitor dapagliflozin, with the aid of positron emission tomography 
(PET) and a labeled glucose analogue tracer 2-deoxy-2-[18F]fluoro-D-glucose ([18F]-
FDG). 
 12
2 Review of the Literature 
2.1 Role of insulin in glucose and lipid metabolism 
Human cells use mainly glucose and fatty acids to fulfill their energy needs. Both 
glycolysis and the degradation of fatty acids via β-oxidation produce acetyl 
coenzyme A (Ac-CoA), which serves as a substrate to the tricarboxylic acid cycle. 
After entering the cycle, Ac-CoA is further oxidized to generate adenosine 
triphosphate (ATP), which in turn is required for cellular survival and functions. The 
preferred substrate varies in different tissues and changes according to, for example, 
nutritional status and physical activity (Goodpaster & Sparks, 2017). While changes 
in the levels of circulating nutrients after a meal can alter tissue metabolism per se, 
the most important regulator of whole-body metabolism in the postprandial state is 
the hormone insulin, which is secreted by the pancreas (Samuel & Shulman, 2016). 
2.1.1 Insulin structure and secretion 
Insulin is a peptide hormone secreted in response to nutrient availability in the 
circulation by pancreatic β-cells in islets of Langerhans, which constitute 1% to 2% 
of the pancreas volume. Insulin is first synthesized as preproinsulin in the rough 
endoplasmic reticulum (RER) and then transformed into proinsulin after a signal 
sequence is removed. Proinsulin is folded, transported to the trans-Golgi network, 
and packed into immature secretory granules. During granule maturation, proinsulin 
is divided into insulin and C-peptide, and finally, the ready granules are stored either 
in readily releasable pools responsible for the first phase of insulin secretion or in 
the reserved pool responsible for delayed second-phase secretion (Hou et al., 2009) 
(Figure 1). 
Figure 1. Production of insulin. First, a 
signal peptide is removed from 
preproinsulin to form proinsulin. This is 
followed by the formation of three 
disulfide bonds. Finally, by cleavage of C-
peptide, proinsulin is converted to mature 
insulin, which consists of an A and B 
chain that are joined together. 
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Glucose is the most important regulator of insulin secretion, with even slight increase 
in blood glucose triggering changes in the release of the hormone within minutes. In 
addition to glucose, other nutrients, such as fatty acids and amino acids, can stimulate 
insulin secretion, while incretin hormones secreted by the gut after digestion 
(glucagon-like peptide-1 [GLP-1], glucose-dependent insulinotropic peptide [GIP], 
cholecystokinin [CCK], and peptide YY [PYY]) can add to the secretion-promoting 
effect of glucose. Glucagon, secreted by pancreatic α-cells in response to a lowering 
of blood glucose; somatostatin, excreted postprandially; and adrenaline and 
noradrenaline (epinephrine and norepinephrine), excreted during stress and exercise, 
are known to inhibit the release of insulin (Rutter et al., 2015). In addition, leptin, 
which is secreted by adipocytes, inhibits insulin secretion, possibly to reduce nutrient 
storing (Kieffer et al., 1997).  
2.1.2 Insulin signaling 
An insulin signaling cascade starts from insulin’s binding to the IR, or in lesser 
affinity, to the homologous insulin-like growth factor-1 receptor (IGF1R), on the 
plasma membrane. There are two isoforms of the receptor: IR-A and IR-B. The latter 
has a more central role in adult metabolism, and the former likely plays a role in cell 
survival and mitosis, with a disproportionate increase in expression of IR-A over IR-
B associated with insulin resistance, aging, and neoplastic cell proliferation (Belfiore 
et al., 2017). 
An IR is a tyrosine kinase receptor and consists of four parts: two extracellular 
α-units and two transmembrane β-units. The binding of insulin to the α-subunits 
activates the β-subunits, which further activate intracellular substrates, such as the 
insulin receptor substrate (IRS) proteins. Activation of the IRS results in the 
recruitment of phosphoinositide 3-kinase (PI3K), which further phosphorylates 
phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-
triphosphate (PIP3), both of which are phospholipids bound to plasma membrane. 
This results in a translocation of phosphoinositide-dependent kinase-1 (PDK-1) to 
the membrane (Boucher et al., 2014).  
Serine/threonine kinase protein kinase B (PKB or AKT) is consequently 
transported to the membrane and is phosphorylated by PDK-1; however, it also 
requires phosphorylation by mammalian target of rapamycin complex 2 (mTORC2) 
to reach full activation (Sarbassov et al., 2005). There are three isoforms of AKT 
kinases, which, despite their highly homologous structure, are coded by different 
genes and seem to have different roles in cell metabolism and survival. AKT1 (or 
PKBα) is the main isoform in all tissues, while AKT2 (or PKBβ) is mostly active in 
insulin-sensitive tissues (skeletal muscle, liver, and AT) and is considered to be 
crucial for insulin-mediated glucose and fatty acid metabolism (Gonzalez & 
Aino Latva-Rasku 
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McGraw, 2009), although a more significant role of ATK1 in skeletal muscle lipid 
metabolism has also been reported (Bouzakri et al., 2006). AKT3 (PKBγ) is enriched 
in the brain and is required for normal brain development (Gonzalez & McGraw, 
2009). Furthermore, phosphorylated AKT has several substrates, and in addition to 
tissue metabolism, it plays an important role in cell survival, growth, tissue 
development, and angiogenesis.  
Concerning metabolism, the following are the most important reactions 
following the binding of insulin to the IR and the activation of the PI3K/AKT 
pathway (Figure 2):  
1. Increase in insulin-stimulated GU by inactivation of TBC1D1 and TBC1D4 
(AS160), resulting in transportation and fusion of glucose transporter 4 
(GLUT4) vesicles to the plasma membrane (Leto & Saltiel, 2012).  
2. Increase in glycogen synthesis by inactivation of glycogen synthase kinase-
3 (GSK3) (Sutherland et al., 1993) or via another pathway (Wan et al., 2013). 
3. Suppression of EGP in the liver and kidneys by inhibiting the function and 
interaction of transcriptional factor forkhead box O (FOXO) and 
transcriptional cofactor peroxisome proliferator-activated receptor γ 
coactivator 1α (PGC-1α), resulting in decreased expression of 
gluconeogenic genes (Puigserver et al., 2003). 
4. Increase in lipid synthesis in the liver either by activating mammalian target 
of rapamycin complex 1 (mTORC1), which induces activation of sterol 
regulatory element-binding protein 1 (SREBP-1) (Yecies et al., 2011), or 
indirectly by inhibition of FOXO, which enables activation of pyruvate 
dehydrogenase complex (PDC), resulting in enhanced glycolysis and 
production of precursors for lipogenesis (Jeong et al., 2012). 
5. Stimulation of glycolysis by activating glucokinase in the liver (Foretz et al., 
1999) and hexokinase II in skeletal muscle (Vogt et al., 2000), which convert 
glucose into glucose-6-phosphate (G6P). 
6. Suppression of lipolysis and promotion of lipogenesis in AT (Roden & 
Shulman, 2019). 
7. Decreased fatty acid oxidation in the liver via inhibition of PGC-1α (Li et 
al., 2007). 
Other than the pathways downstream from AKT, PDK-1 also activates atypical 
protein kinase C (aPKC), which is required for insulin-stimulated hepatic lipid 
synthesis and GLUT4 translocation (Farese & Sajan, 2010). 
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Figure 2. Effects of activation of insulin signaling cascade on cellular glucose and lipid metabolism. 
Adapted from Boucher et al. (2014) with a permission from publisher, © Cold Spring Harbor 
Laboratory Press. 
2.1.3 Effects of insulin on tissue metabolism in normal 
physiology 
Increased substrate storing in the liver 
The liver consists mostly (~80%) of hepatocytes, which use fatty acid oxidation as 
their main energy source during fasting, but switch to using glucose for fuel in the 
postprandial state when circulating carbohydrate levels increase. Glucose is 
primarily transported to hepatocytes via insulin-independent glucose transporter 2 
(GLUT2). This transporter has a high capacity but a low affinity to binding glucose, 
allowing it to carry glucose efficiently using facilitative diffusion, and it enables 
bidirectional transportation over the membrane (Rui, 2014). 
The liver plays a distinct role in handling different substrates derived either from 
the intestines via the portal vein in the postprandial state or from other tissues during 
fasting and physical strain (Figure 3). During fasting, the liver takes up fatty acids 
secreted by white adipose tissue (WAT) and transforms them to glucose 
(gluconeogenesis). Thereafter, glucose from gluconeogenesis or from hepatic 
glycogen storages can be released into circulation (the process of EGP) to be used 
by tissues for which the availability of glucose is essential, most importantly in the 
Aino Latva-Rasku 
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brain. The liver also takes up fatty acids that have been packed in chylomicrons by 
intestinal enterocytes or that are derived from lipolysis in AT, and it is able to store 
fatty acids as TAGs or pack and secrete them in very-low-density lipoproteins 
(VLDLs) to be consumed by or stored in peripheral tissues (Rui, 2014).  
In the postprandial state, the increased glucose level results in increased GU in 
the liver, while insulin has no major direct effect on glucose transportation. However, 
as insulin promotes the expression of glucokinase, glucose is rapidly converted into 
G6P, which in turn increases GU into hepatocytes. In addition to the direct effects of 
insulin, an abundance of G6P also supports postprandial glycogen formation (Roach 
et al., 2012). 
Considering postprandial whole-body glucose homeostasis, insulin’s ability to 
inhibit hepatic endogenous glucose production (EGP) is more important than the 
effects on liver GU. While G6P again works as an allosteric regulator and inhibits 
the breakdown of glycogen, insulin is also a potent suppressor of glycogenolysis and 
EGP either via direct effects or by suppressing WAT lipolysis and subsequent 
hepatic gluconeogenesis (Perry et al., 2015; Titchenell et al., 2015). 
Both insulin and the rise in carbohydrate availability after a meal drive the 
process of converting excess glucose into fatty acids (de novo lipogenesis), which 
are stored as TAGs in the liver and can be released during fasting, while insulin limits 
the release of fatty acids packed in VLDLs in the fed state (Sparks et al., 2012). 
Insulin also inhibits fatty acid oxidation in the liver, resulting in decreased synthesis 
of ketone bodies, which are important nutrients during extended fasting (Li et al., 
2007).  
Shift to glucose oxidation and storing in skeletal muscle  
Like the liver, skeletal muscle uses mostly fatty acids for fuel during fasting. 
However, in the fed state, skeletal muscle accounts for the majority (60–80%) of 
insulin-stimulated GU, as insulin rapidly mobilizes GLUT4s into the cell membrane, 
followed by a switch from fatty acid uptake and oxidation to glucose oxidation (Mäki 
et al., 1998; Cartee, 2015; Goodpaster et al., 2017). 
Another important process stimulated by insulin is the increased glycogen 
synthesis in the postprandial state, as skeletal muscle requires swiftly available 
glucose to produce energy during physical strain at higher intensities when the 
energy needs are no longer met solely by circulating fatty acids (Romjin et al., 1993). 
Furthermore, during exercise, when the mitochondrial capacity of producing energy 
from pyruvate acquired from glycolysis is exceeded, excess pyruvate is converted to 
lactate, which can then be used as an energy source by skeletal muscle—or more 
efficiently by the myocardium and the brain—or converted back into pyruvate in the 
liver (Brooks, 2018) (Figure 3). 
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Increased storing and reduced release of fatty acids in white adipose tissue 
White adipose tissue (WAT), which serves as the reservoir for excess metabolic fuel 
by storing fatty acids as TAGs, is also capable of de novo lipogenesis and re-
releasing fatty acids and glycerol when circulating nutrients are scarce (Bódis & 
Roden, 2018). Glucose uptake into WAT results via insulin-mediated transport by 
GLUT4, with WAT accounting for 5–10% of postprandial glucose disposal 
(Virtanen et al., 2002). The more essential effects of insulin result from activation of 
the mTORC1-SREBP1-pathway, followed by increased storing of fatty acids as 
TAGs and suppression of lipolysis, as well as increased de novo lipogenesis, 
although the latter remains at a lower rate in WAT than in the liver in the postprandial 
state (Bódis & Roden, 2018). Insulin also enhances the uptake of fatty acids into 
WAT by increasing fatty acid transport protein 1 (FATP1) translocation to the 
plasma membrane, as well as by increasing the expression and activity of lipoprotein 
lipase (LPL), an enzyme required for the hydrolysis of TAGs into fatty acids and 
glycerol, which can be taken up by adipocytes (Czech et al., 2013). 
Stimulated glucose uptake into brown adipose tissue 
Brown adipose tissue (BAT) is mainly located in supraclavicular and paravertebral 
depots in adults. While it shares some metabolic functions and structures with WAT, 
its prominent feature is the expression of uncoupling protein-1 (UCP1), which, by 
blocking the negative feedback loop of mitochondrial levels of high ATP and low 
ADP, enables a high rate of fatty acid oxidation, resulting in thermogenesis during 
cold exposure (Carpentier et al., 2018). While insulin can increase the level of BAT 
GU up to fivefold (Orava et al., 2011), the rate of cold-induced thermogenesis 
depleting intracellular TAG storages and circulating fatty acids seems to be 
independent of insulin effects (Blondin et al., 2015). 
Brain glucose metabolism 
The brain relies almost exclusively on glucose as fuel, using 20% of the whole-body 
glucose supply, although it can also use ketone bodies produced by the liver during 
extended fasting, and it seems to prefer lactate when it is available (Aalling et al., 
2018). Glucose is first transported across the blood-brain barrier (BBB) down the 
concentration gradient via facilitative transport by glucose transporter 1 (GLUT1) 
(Pardridge et al., 1990). Neurons express mainly GLUT3 transporters, which have a 
higher affinity and capacity for glucose than GLUT1, whereas astrocytes—the main 
cell type in the brain—take up glucose mostly via GLUT1 transporters and are also 
able to store some glucose as glycogen. Likely in addition to direct GU via GLUT3, 
neurons use lactate provided by astrocytes to fulfill their energy needs in response to 
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neuronal activity (“astrocyte-neuron-lactate shuttle”) (Pellerin & Magistretti, 1994), 
though some consider the evidence to still be controversial (Mason, 2017). 
Although brain glucose metabolism has previously been thought to be insulin-
independent, and central insulin has been thought to serve mainly as a signal of 
satiety, neurons have been shown to express both IRs and GLUT4 and to respond to 
insulin stimulus by increasing GU (Reno et al., 2017). In contrast, in astrocytes, 
insulin does not seem to increase GU despite expression of GLUT4, but it does 
stimulate glycogen synthesis (Heni et al., 2011). While supraphysiological 
circulating insulin levels do not produce a significant effect on the brain GU 
compared to fasting in healthy, lean subjects (a ~3% to 4% increase) (Hirvonen et 
al., 2011), brain GU was 15% lower during hypoinsulinemia compared to fasting 
insulin levels (Bingham et al., 2002), suggesting that insulin might play at least a 
minor role in brain glucose metabolism. 
 
Figure 3. Glucose and lipid fluxes directly or indirectly promoted (black arrows) or inhibited (dashed 
arrows) by insulin in the postprandial state. In the liver, insulin promotes the conversion of glucose 
into glucose-6-phosphate and glycogen synthesis, which enhances glucose uptake; the conversion 
of excess carbohydrates into fatty acids (de novo lipogenesis); and their storage in the liver as 
triacylglycerols (TAGs), while inhibiting glycogenolysis and the release of TAGs in very low -density 
lipoprotein (VLDL) particles. In skeletal muscle, insulin stimulates glucose uptake and 
glycogenesis, consuming carbohydrates as the primary substrate for energy metabolism, and 
inhibits glycogenolysis. In white adipose tissue, insulin increases the uptake of glucose and fatty 
acids and promotes their storage as TAGs, while inhibiting the reverse processes. Glucose is the 
primary source of energy for the brain, with the uptake rate normally being near constant 
independently of circulating insulin levels. 
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2.2 Insulin and the brain in normal physiology 
2.2.1 Metabolic inputs from the periphery to the brain 
A large body of evidence has recognized the brain as playing a central role in 
regulating feeding behavior and energy homeostasis, with the brain collecting 
information about substrate availability in the circulation, as well as about nutritional 
status via endocrinal and neural pathways from peripheral tissues (Schwartz et al., 
2000; Kim et al., 2018). 
 Research has mostly focused on the role of the hypothalamus in sensing and 
regulating brain responses to metabolic cues, with the arcuate nucleus (ARC) serving 
as the first-response area to a variety of signals. The hypothalamic ARC consists of 
agouti-related protein/neuropeptide Y neurons (Agrp/NPY), inhibited by insulin and 
leptin (Hahn et al., 1998), and pro-opiomelanocortin/cocaine- and amphetamine-
regulated transcript neurons (POMC/CART), which are activated by signals of satiety 
and adiposity (Elias et al. 1998). These neurons transmit the afferent signals to further 
locations across the CNS, most the notably paraventricular nucleus, ventromedial 
nucleus, and dorsomedial nucleus (Schwartz et al. 2000). The nucleus of the solitary 
tract (NTS), located in the brain stem, likely plays an important role in a) collecting 
inputs both from the hypothalamic pathway and from the periphery and b) coordinating 
the response resulting in altered eating behavior (Schwartz et al., 2000) (Figure 4). 
Figure 4. Cues of satiety, hunger, feeding, and body adiposity can be transmitted to the 
hypothalamus via direct receptor binding, with the activation of POMC/CART neurons and the 
inhibition of AgrP/NPY neurons resulting in anorexigenic responses. The signals are communicated 
to the brainstem via second-order neurons in different hypothalamic nuclei. Another route is reverse 
signaling from the brainstem to the hypothalamus and cortical regions, stimulated by afferent 
neuronal routes or receptor activation in the hindbrain. ARC: arcuate nucleus, NTS: nucleus of the 
solitary tract, SNS: sympathetic nervous system, BAT: brown adipose tissue, FFAs: free fatty acids. 
Based on Porte et al. (2002) and Schwartz et al. (2000). 
Aino Latva-Rasku 
 20
Insulin levels are affected both acutely, by eating, and continuously, by body 
adiposity (or, more precisely, the associated insulin sensitivity [Schwartz et al., 
1997]), and its central effects on reducing food intake and body mass have long been 
recognized (Woods et al., 1979). The role of central insulin signaling in energy 
homeostasis is summarized in the next chapter. 
Leptin is secreted by the AT, with the circulating concentrations increasing in 
line with an increase in body fat mass (Considine et al., 1996) and AT insulin-
stimulated GU (Mueller et al., 1998). Soon after its discovery, leptin’s lowering 
effect on body weight and food intake and its stimulating effect on energy 
expenditure (Halaas et al., 1995) were attributed to its central effects (Campfield et 
al., 1995), and it has an established role in communicating with the brain about long-
term energy balance (Schwartz et al., 2000). WAT has also been proposed to signal 
the brain via paracrine, endocrine, and neuronal pathways (Guilherme et al., 2019). 
In the postprandial state, the secretion of GLP-1, CCK, and PYY from the small 
intestine increases, while the secretion of ghrelin is inhibited. All of these hormones 
have been associated with the central regulation of eating behavior, with the 
aforementioned changes inducing satiety. In addition to a purely endocrinological 
approach (the secreted hormones reaching the brain via circulation), a variety of 
routes combining endocrinological and neuronal signaling (mainly via afferent vagal 
nerve ends) have been suggested (Steinert et al., 2017). 
Suprascapular BAT depots are also considered to participate in regulating 
feeding behavior via afferent signals to the brain (Glick, 1982; Cannon & 
Nedergaard, 2004). Consuming carbohydrates has been shown to stimulate BAT 
thermogenesis and activate the sympathetic nervous system (SNS) (Welle et al., 
1981), with the hypothesis of a functional BAT-brain axis being further supported 
by the existence of both an afferent and efferent SNS neural loop between the tissues 
(Ryu et al., 2015). Interestingly, gut hormone secretin is also able to stimulate BAT 
directly, as well as induce satiety and reduce food intake (Li et al., 2018). It has even 
been suggested that diurnal changes in BAT activity orchestrate the daily feeding-
fasting cycle (Blessing et al., 2013), but this view is not supported by all (Cannon & 
Nedergaard, 2004). 
While an increased availability of glucose and long-chain FFAs does not seem 
to affect brain metabolism or body weight, hypothalamic sensing of these nutrients 
has been reported to participate in regulating hepatic EGP (Grayson et al., 2013). 
2.2.2 Transportation of insulin to central insulin receptors 
Despite that the central nervous system (CNS) is likely able to produce some insulin, 
its effect on central and peripheral metabolism remains vague (Lacroix et al., 2008; 
Mazucanti et al., 2019), and the majority of insulin in cerebrospinal fluid (CSF) is 
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widely considered to originate from circulation (Margolis et al., 1967; Banks, 2004). 
Insulin is first transported across the BBB by receptor-mediated endocytosis (King 
& Johnson, 1985), albeit that receptor knock-out models have shown that there is 
likely another route as well (Rhea et al., 2018). The transportation is characterized 
by fast saturability as the increase in CSF insulin concentration plateaus already 
before a significant lowering of plasma glucose levels can be seen (Baura et al., 1993; 
Banks et al., 1997). Interestingly, the rate of insulin transportation varies between 
different brain regions in mouse models, with the olfactory bulb showing remarkably 
higher rates (Banks et al., 1999), followed by the pons, medulla, and hypothalamus 
(Banks & Kastin, 1998), while little or no transport occurs in the occipital cortex 
(Banks & Kastin, 1998). Furthermore, the expression of IRs as well as IRS 
demonstrates a similar distribution across the brain, with higher concentrations 
present in areas with enhanced insulin transportation capacity (Havrankova et al., 
1978; Kleinridders et al., 2014).  
2.2.3 Assessing the effects of central insulin signaling in 
clinical studies 
In experimental settings, insulin’s impact on brain metabolism and function has been 
studied in animal models by administering insulin intracerebroventricularly or into 
the carotid arteries to isolate the central effects from confounding peripheral effects. 
Due to the invasiveness of these techniques, studies on humans have been performed 
by administering insulin intranasally. In rodents, intranasal insulin (INI) reaches the 
brain via olfactory nerve tracts while avoiding the tightly regulated transportation 
across the BBB, and this is considered to occur in humans as well (Renner et al., 
2012). This hypothesis is supported by a report showing a more rapid and strong 
increase in CSF insulin concentration after intranasal administration than what 
should ensue if insulin passed via circulation first (Born et al., 2002). The approach 
has since been applied by several research groups, and it has proven to be applicable 
in reproducing results similar to those seen in animal models (Benedict et al., 2011; 
Heni et al., 2012; Dash et al., 2015). 
Another, more indirect way in which to investigate the effects of brain insulin 
signaling is via pharmacological activation (by diazoxide) or blockage (by 
sulphonylureas) of central KATP channels. In the pancreas, activation of these 
channels mediates insulin secretion, whereas in the brain, their activation in 
glucoregulatory neurons by insulin is essential for producing peripheral effects 
(Spanswick et al., 2000; Obici et al., 2002; Pocai et al., 2005).  
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2.2.4 Brain insulin signaling as a regulator of central and 
peripheral metabolism  
After initial recognition of insulin as a regulator of satiety, a multitude of effects 
independent of or enhancing insulin’s direct actions on peripheral tissues have been 
described (Figure 5). 
Figure 5. Central insulin sensing produces responses in several tissues and on the whole-body 
level. EGP: endogenous glucose production, BAT: brown adipose tissue, WAT: white adipose 
tissue, GU: glucose uptake (Kleinridders et al., 2014; Heni et al., 2015a). 
Induction of satiety and weight loss 
Insulin has the ability to directly affect the hypothalamus, reduce food intake, and 
promote satiety and weight loss. These effects were the first metabolic responses to 
be reported (Debons et al., 1970; Woods et al., 1979), and they have also been 
reproduced in humans (Hallschmid et al., 2004; Benedict et al., 2008; Jauch-Chara 
et al., 2012). Interestingly, direct insulin delivery to the brain via 
intracerebroventricular (i.c.v.) administration in mice or intranasally in humans 
seems to affect males more strongly, whereas female subjects exhibit a lesser or no 
effect on feeding behavior or body weight (Clegg et al., 2003; Hallscmid et al,. 2004; 
Benedict et al., 2008). 
The mechanisms underlying the anorexigenic response are still incompletely 
understood. For one, insulin seems to reduce the appeal of food by decreasing 
olfactory capacity (Ketterer et al., 2011; Brünner et al., 2013) and suppressing the 
reaction induced by visual food cues (Guthoff et al., 2010). Enhanced brain 
metabolism after INI, measured as ATP concentration, has also been suggested to 
serve as a signal to reduce food intake (Jauch-Chara et al., 2012). 
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Inhibitory effect on endogenous glucose production and controversial 
results on hepatic lipid metabolism 
The role of central insulin signaling in the suppression of hepatic glucose production 
(EGP) has been reported in several animal and human studies. In rodents, this effect 
has been attributed especially to insulin’s ability to activate the KATP channels of the 
mediobasal hypothalamus or dorsal vagus complex, resulting in the suppression of 
gluconeogenic gene transcription or the inhibition of EGP (Obici et al., 2002; Pocai 
et al., 2005; Könner et al., 2007; Filippi et al., 2012). The centrally regulated 
suppression of hepatic EGP has been shown to be associated with the activation of 
hepatic interleukin-6 (IL-6), and to follow the activation of signal transducer and 
activator of transcription-3 (STAT3) (Inoue et al., 2006; Koch et al., 2008).  
In contrast, experiments performed in dogs under pancreatic clamp conditions, 
implying the more physiological 3:1 ratio of hepatic and CSF insulin concentrations, 
revealed no change in EGP after i.c.v. insulin administration despite an increase in 
STAT3 phosphorylation. However, in these studies, hepatic glycogen synthesis was 
augmented as a result of the inhibition of GSK gene transcription and protein 
expression (Ramnanan et al., 2011, 2013). The same group of researchers later 
stressed that despite these modest findings, insulin’s direct effect on hepatic 
metabolism prevails over the central regulation (Edgerton et al., 2006; Ramnanan et 
al., 2012). 
Results from human studies, performed almost exclusively on males, have 
demonstrated that both INI and activation of central KATP channels with diazoxide 
enhance insulin’s inhibitory effect on EGP during systemic hyperinsulinemia (Dash 
et al., 2015; Heni et al., 2017; Kishore et al., 2012). Under fasting conditions, INI 
has no effect on EGP (Gancheva et al., 2015; Plomgaard et al., 2019), whereas one 
study, using diazoxide with somatostatin to suppress endogenous insulin production 
and applying intravenous (i.v.) insulin comparable to fasting levels, showed a 
reduction in EGP (Esterson et al., 2016). These findings support the notion of an 
additive, rather than an essential role of central insulin signaling on regulating EGP. 
This view is also confirmed by the almost unaltered postprandial glucose metabolism 
in subjects lacking a direct neuronal contact between the brain and the liver due to 
liver transplantation (Perseghin et al., 1997a).  
Studies regarding INI’s effects on hepatic lipid metabolism have produced more 
controversial results. In experiments performed under fasting conditions, a single 
dose of INI has been reported to increase hepatic TAG content (Gancheva et al., 
2015) and also inhibit triglyceride-rich lipoprotein secretion (Xiao et al., 2017), 
while four weeks of daily dosing resulted in no effect on hepatic lipid content 
(Scherer et al., 2017). The results from mouse studies do not form a clear conclusion 
either. On the one hand, one report found that i.c.v. insulin acutely stimulates hepatic 
TAG excretion, resulting in reduced hepatic TAGs when administered chronically 
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(Scherer et al., 2016). On the other hand, insulin has been shown to suppress NPY-
expressing neurons (Qiu et al., 2014), which should act against the initiation of 
VLDL secretion by these hypothalamic neurons (Stafford et al., 2008).  
Promotion of brown adipose tissue activity and white adipose tissue 
lipogenesis 
Thermogenesis in BAT in the postprandial state has been reported in animal models 
as well as in humans, and it likely contributes to the afferent signals of hunger and 
satiety, while also being upregulated by central stimuli induced by insulin and other 
hormones (Cannon & Nedergaard, 2004). In a mouse model, i.c.v. insulin 
administration has been shown to increase BAT activity via SNS activation 
(Rahmouni et al., 2004). Accordingly, in male human subjects, INI has been found 
to increase mean postprandial thermogenesis, an indicator of BAT activity (Benedict 
et al., 2011). 
In the same study by Benedict et al. (2011), INI decreased postprandial levels of 
circulating free fatty acids (FFAs), suggesting the central regulation of postprandial 
lipolysis. Indeed, in mouse models, acute and chronic administration of insulin to the 
brain has been shown to promote lipogenesis and reduce lipolysis in subcutaneous 
and visceral AT during fasting and hyperinsulinemic-euglycemic clamp conditions 
(Koch et al., 2008; Scherer et al., 2011; Coomans et al., 2011a), possibly via SNS 
activation (Scherer & Buettner, 2011). However, the studies in humans that have 
accounted for the confounding increase in circulating insulin levels after INI have 
not detected any effects on systemic lipolysis measured as changes in FFA or 
triglyceride levels during fasting or hyperinsulinemia (Gancheva et al., 2015; Dash 
et al., 2015; Heni et al., 2015b; Xiao et al., 2017). 
Effects on peripheral glucose uptake 
The effects of brain insulin signaling on peripheral glucose metabolism are more 
controversial. Two studies in mice have suggested that central insulin stimulus 
increases whole-body insulin-stimulated glucose utilization, measured as the glucose 
infusion rate (GIR) required to sustain normoglycemia during hyperinsulinemia. 
However, the authors have attributed this to a decrease in EGP and not to enhanced 
peripheral GU (Coomans et al., 2011b; Filippi et al., 2012), and one study reported 
no change in the glucose rate of disappearance (Rd) (Obici et al., 2002). However, 
there have also been reports of a) a remarkable 59% decrease in insulin-stimulated 
skeletal muscle GU following the inhibition of hypothalamic insulin signaling by 
blocking central KATP channels (Coomans et al., 2011b) and b) increased skeletal 
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muscle glycogenesis and whole-body glucose turnover following i.c.v. insulin 
infusion (Perrin et al., 2004). 
Furthermore, in humans, applying INI has been reported to increase whole-body 
insulin sensitivity, determined as the homeostatic model assessment for insulin 
resistance (HOMA-IR) (Heni et al., 2012), or insulin-stimulated glucose 
consumption represented by GIR as well (Heni et al., 2014). Although in a later study 
by the same group, only a trend toward a higher GIR remained after taking into 
account the confounding effects of spillover from INI to circulation (Heni et al., 
2017). The rate of glucose disappearance has not been altered by INI (Dash et al., 
2015; Heni et al., 2017) or diazoxide (Kishore et al., 2012) in the presence of 
systemic hyperinsulinemia and normoglycemia. 
2.3 Insulin resistance 
Insulin resistance is usually referred to as the failure of an insulin stimulus to induce 
primarily metabolic changes in specific tissues or on the whole-body level, and it 
was first recognized in the 1930s, when a subgroup of hyperglycemic patients was 
reported not to respond to insulin treatment (Himsworth, 1936). The condition has 
since been recognized as the major feature of T2D, and the development, 
manifestations in different tissues, and treatment of insulin resistance continue to be 
targets of fervent investigations. A multitude of genetic and epigenetic factors, as 
well as the sedentary lifestyle associated with obesity and nutrient excess, and 
changes in gut microbiota have been shown to contribute to increasing the risk of 
insulin resistance. 
The primary defect leading to systemic insulin resistance is impaired GU into 
skeletal muscle in the postprandial state and a subsequent reduction in glycogen 
synthesis (DeFronzo et al., 2009), supported by studies in the offspring of T2D 
patients (Perseghin et al., 1997b; Kashyap et al., 2004; Ferrannini et al., 2003; Vaag 
et al., 1992). As skeletal muscle should be the predominant site of postprandial GU, 
impaired GU leads to sustained hyperglycemia, which is met by increased insulin 
secretion by the pancreatic β-cells. The pancreas is usually capable of accounting for 
hyperglycemia for a long time, with increased insulin levels being the first signs of 
insulin resistance. A failure in this response results in a progression towards T2D 
and usually starts to occur years before the diagnostic criteria of the disease are 
fulfilled (Tabák et al., 2009; Ohn et al., 2016). 
Chronic hyperinsulinemia has disadvantageously been shown to adversely cause 
insulin resistance, mostly attributed to further reduced glycogen synthesis in skeletal 
muscle (Del Prato et al., 1994; Koopmans et al., 1999; Iozzo et al., 2001). In the 
liver, sustained hyperinsulinemia does not have a primary effect on EGP (Del Prato 
et al., 1994; Koopmans et al., 1999), but increases hepatic de novo lipogenesis and 
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circulating FFA levels (Koopmans et al., 1999). Moreover, in the liver and AT, 
hyperinsulinemia initially promotes TAG storing. Increased WAT mass is, however, 
susceptible to hypoxia, inflammation, and dysfunctions in lipid-storing capacity, 
which contribute to aggravating the situation further (Czech et al., 2017). Chronic 
hyperglycemia (glucotoxicity) (Rossetti et al., 1990; Burén et al., 2003) and 
hyperlipidemia (lipotoxicity) (DeFronzo, 2010) can also have detrimental effects on 
insulin sensitivity. Tissue-specific alterations in insulin resistance are reviewed in 
Figure 6. 
Figure 6. Manifestations of insulin resistance in different tissues and the resulting metabolic 
crosstalk between tissues. Impaired insulin sensitivity is associated with reduced insulin-stimulated 
glucose uptake in most peripheral tissues, whereas in the brain, the result seems to be the opposite. 
In adipose tissue, the key feature is inadequate suppression of lipolysis, resulting in increased levels 
of circulating glycerol and FFAs. These serve as precursors for gluconeogenesis in the liver, where 
excess glucose is released back into circulation or directed towards lipogenesis, resulting in an 
accumulation of ectopic fat. In skeletal muscle, fatty acids are also stored in excess as TAGs, 
whereas glycogen synthesis is decreased. Inflammatory processes have also been recognized to 
alter substrate utilization. FFAs: free fatty acids, TAG: triacylglycerol, VLDL: very-low-density 
lipoprotein. Based on Samuel and Shulman (2016) and Roden and Shulman (2019). Illustrated 
using SMART (Servier Medical ART; https://smart.servier.com) under the terms of the Creative 
Commons Attribution 3.0 Unported license (CC BY 3.0). 
Review of the Literature 
 27 
Genetic predisposition to insulin resistance 
Applying genome-wide association studies to large populations has currently led to 
the recognition of ~403 genetic loci in which a) mutations can be associated with 
increased risk of T2D (Mahajan et al., 2018) and b) over 80 common genetic variants 
can be associated with a modest increase in the lifetime risk of T2D (Fuchsberger et 
al., 2016). In addition to common, small effect variants, low-frequency or rare 
variants with larger effects, as well as epigenetic factors, contribute to the heritability 
of T2D. However, part of the known variants are associated with a failure in insulin 
secretion or an increased prevalence of obesity rather than insulin resistance. 
Moreover, for many variants, the functional effects are not easy to target, as they are 
not located in the exome—the area of the gene coding proteins—but in the intron 
areas regulating protein expression. 
Genetic profiling in insulin resistance, possibly later enabling precision medicine 
and screening for people at higher risk of T2D, would require a better understanding 
of the functional effects of single variants. Performing genotype-based callback 
studies on variant carriers could be used to elucidate the significance of a single 
mutation on tissue metabolism, starting from variants with known effects on insulin 
sensitivity. 
One candidate for further phenotyping is a low-frequency coding variant 
p.Pro50Thr in the AKT2 gene, which is present in 1.1% of people with Finnish 
ancestry, but has not been reported in other populations (Manning et al., 2017). 
Variant carriers demonstrated hyperinsulinemia and impaired insulin sensitivity 
during a 2-hour oral glucose tolerance test (OGTT), and they had higher 
susceptibility to T2D, with further in vitro studies confirming a partial loss of 
phosphorylation of the AKT2 protein, resulting in impaired glycogen synthesis in 
skeletal muscle (Manning et al., 2017). Previous studies in animal (specifically mice) 
AKT2 knock-out models support the functional role of the loss-of-function variant, 
as these mice presented impaired insulin-stimulated GU and lesser suppression of 
EGP by insulin (Cho et al., 2001; Wan et al., 2013; Garofalo et al., 2003). While the 
role of AKT2 in lipid metabolism has been more controversial, its normal function 
seems to be crucial for lipid handling and for the development and maintenance of 
AT (Leavens et al., 2009; Garofalo et al., 2003) while having a minor effect on 
lipolysis (Koren et al., 2015). Furthermore, in one family, a monogenic loss-of-
function mutation of AKT2 (p.Arg274His/AKT2) has been shown to result in severe 
insulin resistance, similarly led by the impaired inhibition of GSK3 by AKT2 
(George et al., 2004).  
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2.3.1 Tissue-specific alterations in insulin resistance 
Impaired glucose uptake into skeletal muscle 
In skeletal muscle, insulin resistance is usually attributed to a primary defect in 
insulin signaling (Roden & Shulman, 2019). This results in impaired insulin-
stimulated GU, followed by a decrease in glycogen synthesis (Cline et al., 1999).  
However, not only faulty insulin signaling, but also increased availability of fatty 
acids, either from nutrition or resulting from disturbances in AT and hepatic lipid 
metabolism, complicates skeletal muscle insulin resistance. Fatty acids have been 
shown to compete with glucose when available, and during insulin stimulation, they 
inhibit GU (Ferrannini et al., 1983; Yki-Järvinen et al., 1991; Kelley et al., 1993) 
and insulin signaling possibly by inactivating PI-3K and IRS-1 (Dresner et al., 1999; 
Griffin et al., 1999). Furthermore, the excess fatty acid availability and associated 
mitochondrial dysfunction lead to an accumulation of ectopic fat, which further 
impairs insulin sensitivity via increased levels of diacylglycerols (DAGs) and protein 
kinase C (PKC), which inactivates IRS and results in the downregulation of several 
downstream pathways (Yu et al., 2002). 
Reduced lipogenesis in white adipose tissue  
The primary indication of insulin resistance in WAT is impaired lipid storage 
resulting from an inadequate suppression of lipolysis and the stimulation of 
lipogenesis, which also leads to the unphysiological release of fatty acids and 
glycerol in the postprandial state (Roden & Shulman, 2019).  
Insulin resistance in WAT is usually attributed to an increased amount of WAT 
and an increased size of adipocytes, which results in tissue hypoxia and inflammation 
due to insufficient vasculature (Pasarica et al., 2009) and relative mitochondrial 
hypoxia due to excess fatty acids (Lee et al., 2014). Yet, the distribution of AT and 
genetic factors seem to participate in determining whether WAT will become insulin 
resistant (Shungin et al., 2015).  
In addition to primary defects in insulin signaling, as seen in skeletal muscle, 
inflammatory response due to hypoxia is considered another major regulator of 
adipocyte insulin resistance (Bódis & Roden, 2018). Hypoxia-induced secretion of 
cytokines and cell death promote the differentiation of monocytes into M1 
macrophages, which in turn secrete proinflammatory cytokines such as interleukin-
1 and -6 (IL-1, IL-6), and tumor necrosis factor α (TNFα), which can also have 
detrimental effects on insulin sensitivity in different tissues (Thomas & Apovian, 
2017). 
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Interestingly, adipocytes demonstrate reduced insulin-stimulated GU due to 
downregulated GLUT4 expression, whereas no similar change is seen in skeletal 
muscle. Moreover, adipose-tissue-specific GLUT4 knock-out mice demonstrate 
normal WAT development despite impaired insulin-stimulated GU into the tissue, 
combined with secondary insulin resistance in skeletal muscle and liver (Abel et al., 
2001). 
Inadequate suppression of endogenous glucose production in the liver 
Hepatic insulin resistance reflects the changes in other tissues, with insulin’s 
weakened ability to downregulate EGP being usually considered the main feature. 
The background of insulin resistance in the liver lies both in impaired IR binding 
and activation of downstream kinases in hepatocytes (Caro et al., 1986) and in the 
direct and indirect effects of fatty acids on hepatic metabolism and insulin signaling. 
The high rate of EGP has been shown to originate mostly from an impaired 
downregulation of lipolysis by insulin, resulting in an excess of lipid precursors for 
gluconeogenesis in the liver (Perry et al., 2015). Furthermore, lower inhibition of 
glycogenolysis in insulin-resistant subjects (Basu et al., 2005), further impaired by 
excess fatty acids (Boden et al. 2002), and decreased glycogen synthesis (Krssak et 
al., 2004) result in surplus glucose being directed towards de novo lipogenesis.  
In addition to fatty acids from de novo lipogenesis and diet, re-esterification of 
WAT-derived fatty acids plays a major role in TAG accumulation in the liver 
(Donnelly et al., 2005). In an insulin-resistant state, the TAGs are not only stored in 
the liver, but also released in VLDL particles (Choi & Ginsberg, 2011). The 
associated increase in DAGs and PKC, as also seen in skeletal muscle, aggravate 
insulin resistance, and together with stimulation by cytokines, contributes to the 
development of non-alcoholic fatty liver disease (NAFLD) (Shulman, 2014). 
Increased insulin-stimulated glucose uptake in the brain 
Contrarily to other tissues, brain insulin-stimulated GU is increased in insulin-
resistant and obese subjects (Hirvonen et al., 2011; Tuulari et al., 2013; Boersma et 
al., 2018), while there seems to be no significant difference under fasting conditions 
(Hirvonen et al., 2011). Some studies have associated this change with brain 
inflammation, manifesting as hypothalamic astrogliosis in magnetic resonance 
imaging (MRI) studies (Thaler et al., 2012). This would be supported by the finding 
that brain [18F]-FDG is mostly taken up by astrocytes rather than neurons (Zimmer 
et al., 2017); however, this division has also been criticized (Dienel et al., 2018). 
Another theory is that increased brain GU in insulin resistance is reciprocal to 
insulin’s impaired effects on peripheral tissues, and the increase can be translated to 
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insulin’s failure to prevent the brain from being exposed to hyperglycemia (Iozzo & 
Guzzardi, 2019). 
Brain insulin resistance also seems to be associated with defective central 
regulation of EGP, as two groups reporting centrally mediated effects failed to 
demonstrate differences when using the same methods in obese and insulin-resistant 
subjects (Heni et al., 2017; Xiao et al., 2018). Enhanced hepatic TAG accumulation 
by INI was also absent in T2D subjects (Gancheva et al., 2015). 
In addition to tissue metabolism, brain insulin resistance is also associated with 
poorer control of feeding behavior, brain connectivity, and impaired cognitive 
function (Heni et al., 2015; Iozzo & Guzzardi, 2019). It seems that changes in 
glucose metabolism link insulin resistance to cognitive impairment, as brain GU is 
increased in mild cognitive impairment, while hypometabolism is associated with 
progression to Alzheimer’s disease (Ashraf et al., 2015), although it remains 
debatable whether increased GU is the precursor of cognitive decline or a response 
to failing neuronal function. 
2.3.2 Treating insulin resistance 
Lifestyle modifications 
While genetic predisposition to insulin resistance cannot be amended, diet 
interventions, increasing physical activity, and weight loss have all been proven 
successful in preventing the progression from impaired insulin sensitivity to T2D 
(Pan et al., 1997; Tuomilehto et al., 2001; Knowler et al., 2002). 
The favorable effects of weight loss on insulin resistance can be largely 
attributed to a reduction in ectopic fat depots in skeletal muscle and the liver, 
resulting in improved insulin signaling in these tissues. The decline in AT volume 
and the subsequent lower release of fatty acids also results in lower hepatic EGP, 
which alleviates hyperglycemia (Grams &Garvey, 2015). Furthermore, weight loss 
achieved by lifestyle changes, medications, or bariatric surgery have all been proven 
efficient in improving insulin sensitivity (Grams & Garvey, 2015), while bariatric 
surgery has been suggested to affect insulin sensitivity also via several other 
pathways independently of weight loss (Batterham & Cummings, 2016). 
Exercising has been demonstrated to have several beneficial effects on insulin 
sensitivity, even without weight loss (Roberts et al., 2013). A single bout of physical 
activity has been shown to increase skeletal muscle GU for up to 48 hours by 
increasing GLUT4 translocation independently of insulin and by enhancing insulin 
signal transduction, both in healthy and insulin-resistant subjects (Hawley et al., 
2008). In addition, exercise-induced improved oxidative capacity has been 
postulated to promote fatty acid oxidation, resulting in reduced TAG accumulation 
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in skeletal muscle (Hawley et al., 2008), while favorable changes in inflammatory 
biomarkers by exercise have also been reported (Roberts et al., 2013). 
Pharmacological approach 
Some antidiabetic drugs have been suggested to improve insulin sensitivity in 
addition to having glucose-lowering effects: 
Thiazolidinediones (glitazones) activate the nuclear peroxisome proliferator-
activated receptor gamma γ (PPARγ) receptors, resulting in promoted lipogenesis in 
subcutaneous AT and, most importantly, a redistribution of hepatic TAGs into 
subcutaneous WAT (Mayerson et al., 2002). These changes are associated with 
increased insulin-stimulated GU to skeletal muscle (Hällsten et al., 2002), as well as 
improved perfusion and consequently improved GU in AT (Viljanen et al., 2005). 
Sodium-glucose cotransporter 2 (SGLT2) inhibitors act by inhibiting glucose 
reabsorption from the renal proximal tubules. Despite the almost exclusive 
expression of SGLT2 in the kidneys (Wright et al., 2011), previous studies have 
reported improved whole-body insulin-stimulated glucose Rd with the treatment 
(Merovci et al., 2014, 2016; Mudaliar et al., 2014; Daniele et al., 2016, Matsuba et 
al. 2018), suggested to result from improved skeletal muscle GU during 
hyperinsulinemia (Merovci et al., 2014). The latter hypothesis, however, is only 
based on the major role of skeletal muscle in insulin-stimulated GU, and not on a 
direct assessment. SGLT2 inhibitors have also been shown to cause a metabolic shift 
from glucose to fatty acid oxidation and ketone production in the postprandial state 
and during pharmacolocigal hyperinsulinemia (Ferrannini et al., 2014; Daniele et al., 
2016). Interestingly, increased insulin-stimulated glucose disposal has also been 
shown to be accompanied by a counteracting increase in EGP (Merovci et al., 2014; 
Ferrannini et al., 2014).  
Due to calorie loss and increased osmotic diuresis, treatment with SGLT2 
inhibitors also induces significant weight loss (List et al., 2009; Ferrannini et al., 
2013), mostly accounted for by a loss of subcutaneous and visceral AT mass 
(Bolinder et al., 2012). In addition, loss of WAT has been shown to be associated 
with a decrease in liver fat content in T2D patients with NAFLD in several studies 
with different SGLT2 inhibitors (Ito et al., 2017; Shibuya et al., 2018; Eriksson et 
al., 2018; Kuchay et al., 2018). 
GLP1-receptor antagonists lower blood glucose by enhancing β-cell function. 
They have also been suggested to contribute to the regulation of feeding (Htike et 
al., 2017), and they improve whole-body insulin sensitivity (Zander et al., 2002) and 
have beneficial effects on hepatic lipid metabolism (Armstrong et al., 2016). 
However, whether these effects can be solely attributed to the lowering of body 
weight and blood glucose is currently unknown (DeFronzo, 2017), as studies 
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supporting the role of the pleiotropic effects of GLP-1 receptor activation in 
extrapancreatic tissues show partly conflicting results (Jiang et al., 2018; Gil-Lozano 
et al., 2010; Winzeler et al., 2019). 
Furthermore, while metformin has long been the first-line drug in T2D, its 
glucose-lowering mechanisms of action are still not fully understood. However, the 
drug does not seem to directly affect whole-body or skeletal muscle insulin 
sensitivity (Hällsten et al., 2002), and the preeminent effect is usually considered to 
be the promoted suppression of EGP through reduced hepatic gluconeogenesis 
(Hundal et al., 2000).   
2.4 Quantifying insulin sensitivity 
2.4.1 Measures of whole-body insulin sensitivity 
Hyperinsulinemic-euglycemic clamp 
The hyperinsulinemic-euglycemic clamp technique (DeFronzo et al., 1979) is a well-
established approach to measure whole-body insulin-stimulated GU. The method is 
based on rapidly increasing circulating insulin concentration to high physiological 
or supraphysiological levels while maintaining euglycemia (plasma glucose 
concentration 5.0 mmol/L ± 5%) by an i.v. glucose infusion. In insulin-sensitive 
subjects, hyperinsulinemia inhibits EGP by the liver and the kidneys, whereas 
euglycemia should prevent activation of other possibly confounding mechanisms 
regulating glucose metabolism. After an equilibrium phase, the rate of glucose 
infusion approximates the whole-body glucose disposal rate (M-value), and the 
following formula can be used: 
𝑀𝑀 = 𝐺𝐺𝐺𝐺𝐺𝐺 − 𝑆𝑆𝑆𝑆 − 𝑈𝑈𝑆𝑆 
where GIR is the glucose infusion rate, SC is the space correction accounting for 
changes in glucose levels, and UC is the rate of urinary glucose excretion (all 
µmol/kg/min). 
It is also possible to add a somatostatin infusion to the routine protocol to 
suppress the release of endogenous insulin (“pancreatic clamp”). Furthermore, while 
no official threshold exists for insulin resistance, a cutoff point of 28 µmol/min/kg 
lean body mass has been suggested (Stern et al., 2005), with lower values indicating 
impaired insulin sensitivity. 
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Stable isotope techniques 
Applying substrates, such as glucose or fatty acids, labeled with radioactive (e.g. 
tritium, 3H) or non-radioactive (e.g. 13C and 2H) stable isotopes allows for the 
evaluation of their rate of appearance and disappearance (Steele et al., 1956; Dube 
et al., 2013). 3-[3H]-glucose is often used together with the hyperinsulinemic-
euglycemic clamp to allow for the simultaneous determination of glucose 
appearance, namely EGP. The use of dual or triple tracer techniques enables an 
investigation into the transportation and further metabolism of nutrients from meals; 
however, the challenges and inaccuracies resulting from the postprandial non-steady 
state need to be considered (Dube et al., 2013). 
Other estimates of whole-body insulin sensitivity 
As the hyperinsulinemic-euglycemic clamp requires experienced staff, and it can be 
considered time-consuming and invasive, other indices of insulin sensitivity are 
regularly applied, especially when studying larger study populations. 
Whole-body insulin sensitivity can be estimated from fasting laboratory samples 
of glucose and insulin, by using either formulas such as HOMA-IR (Matthews et al., 
1985) or the quantitative insulin sensitivity check index (QUICKI) (Katz et al., 
2000), which mainly reflect hepatic insulin sensitivity. Indices facilitating data from 
an OGTT (Matsuda-ISI [Matsuda & DeFronzo, 1999], the Stumvoll metabolic 
clearance rate (MCR) or ISI [Stumvoll et al., 2000], Gutt [Gutt et al., 2000], and 
OGIS [Mari et al., 2001]) offer additional insight into the postprandial state and 
peripheral insulin sensitivity, while they may fail to differentiate impaired insulin 
secretion from insulin resistance. Matsuda-ISI, or the composite index, is calculated 
by dividing 10,000 by the square root of [fasting glucose x fasting insulin] x [mean 
glucose x mean insulin during OGTT], and it correlates significantly (r = 0.73) with 
M-values (Matsuda & DeFronzo, 1999). As with the hyperinsulinemic clamp, no 
reference range of normal values has been determined. Based on the original 
publication and the cutoff point for the M-value from Stern et al. (2005), Matsuda-
ISI <3 indicates insulin resistance. In another population consisting of non-diabetic 
offspring of T2D patients, the mean Matsuda-ISI was 3.2 for subjects with insulin 
resistance and 6.4 for subjects without insulin resistance (Lorenzo et al., 2015). A 
revised QUICKI that also accounts for fasting non-esterified fatty acids (Perseghin 
et al., 2001) seems to correlate with M-values from the hyperinsulinemic-euglycemic 
clamp equally well as the OGTT-derived models (Otten et al., 2014). 
A minimal model analysis of a frequently sampled i.v. glucose tolerance test 
(FSIVGTT) (Bergman et al., 1987), with additional i.v. insulin or tolbutamide to 
improve accuracy, correlates well with the M-values (Saad et al., 1997), but requires 
cannulation and frequent blood collection over 3 to 4 hours. Furthermore, the 
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FSIVGTT shares some of the limitations of the OGTT and loses reliability in 
subjects with diabetes (Saad et al., 1994).  
Another more invasive method to assess whole-body insulin sensitivity is the 
insulin suppression test (IST) (Shen et al., 1970). This test includes i.v. infusions of 
somatostatin, insulin, and glucose at steady rates, and the level of insulin sensitivity 
is determined by the plasma glucose level 150–180 min after the start of the protocol. 
Compared to the clamp, the IST is as invasive and as laborious, and it can cause 
hypoglycemia in insulin-sensitive subjects and stimulate urinary glucose excretion 
in insulin-resistant subjects.  
2.4.2 Biochemical approaches to measuring tissue-specific 
metabolism in vivo 
Arteriovenous catheterization was the first technique developed to investigate tissue 
metabolism (Zierler, 1961). It is based on a simple model of different concentrations 
of substances in afferent and efferent blood vessels while blood flow is assumed to 
be steady. 
Microdialysis is a more sophisticated technique to measure tissue metabolism 
(Lönnroth et al., 1987), with the inclusion of tissue blood flow measurements 
allowing for a more accurate assessment of, for example, AT lipolysis (Jansson et 
al., 1992), skeletal muscle GU (Peltoniemi et al., 2000), and AT GU (Virtanen et al., 
2001).  
However, the invasiveness of these methods hinders their use in clinical studies, 
and they also only yield results from a small area, which can cause issues in 
heterogeneous tissues unless several catheters are used. While the turnover of small, 
hydrophilic molecules (such as glucose or glycerol) can be reliably measured with 
microdialysis, investigating larger, lipophilic molecules (such as insulin and fatty 
acids) is less feasible due to their membrane adhesion and protein binding. 
2.4.3 Positron emission tomography 
Positron emission tomography (PET) is an imaging technique that enables 
quantitative in vivo studies of tissue metabolism, blood flow, and receptor binding. 
Compared to several previously described approaches, it is non-invasive, and it also 
has the advantage of allowing for a direct investigation of deep tissues. 
For those studies, a ligand suitable for the aim of the study (e.g. 2-deoxy-D-
glucose for studying glucose metabolism) is labeled with a short-lived positron-
emitting radionuclide (e.g. fluorine-18) and administered to the study subject 
typically intravenously, while oral routes of administration and inhalations are also 
possible. After a varying period of time required for the distribution and 
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accumulation of the radiotracer into the target tissues, tissue activity, which 
represents the behavior of the selected ligand, can be measured by using a PET 
scanner.  
Positron emission and operation of a PET scanner 
The most commonly used radionuclides for PET imaging are fluorine-18, carbon-
11, oxygen-15, gallium-68, and nitrogen-13. These positron-emitting nuclides are 
produced by exposing stable, non-radioactive isotopes (such as oxygen-18 to 
produce fluorine-18) to a high-energy beam of protons created by a cyclotron. In 
addition to different half-lives, ranging from ~2 min of oxygen-15 to ~110 min of 
fluorine-18, the chemical properties of the nuclei affect their pairing with different 
ligands. All the nuclei undergo radioactive decay by emitting a positron (β+) that 
shortly, after traveling ~1 mm, collides with an electron (e-). This collision is called 
annihilation, and it results in the creation of two photons (i.e. two 511-keV gamma 
rays) moving approximately 180 degrees to each other (Figure 7). 
These gamma rays can be detected by a PET scanner (Figure 8). The scanner 
usually consists of multiple rings of detectors with scintillation crystals, which can 
absorb gamma radiation and convert it into photons. In analog PET scanners, 
photomultiplier tubes convert the photons from crystals into electrical signals 
(Turkington, 2001), whereas recently developed digital PET scanners record the 
photons directly, resulting in a better signal-to-noise ratio (Nguyen et al., 2015). 
When two detectors identify the two gamma rays produced by annihilation 
simultaneously (within of 6 to 10 nanoseconds), the signal, called a coincidence, is 
registered (Figure 7) (Turkington, 2001). The line between these two detectors is 
called the line of response (LOR), and the source of the annihilation can be localized 
along it based on the relative time difference between registrations.  
 
Figure 7. Detection of an annihilation (“coincidence”) resulting from the collision of the emitted 
proton (β+ particle) and an electron (e-). Originally published by Verel et al. (2005); reprinted with 
permission from publisher © SNMMI. 
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During the PET scan, the number of coincidences between each possible detector 
pair is counted and then reconstructed into cross-sectional images (Figure 8) 
(Turkington, 2001). To measure changes in tracer uptake, the PET scan is usually 
divided into different intervals of time, called frames, ranging from a few seconds to 
10 min. Collecting dynamic data in several short, sequential periods from one area 
allows for the evaluation of tracer fluxes, which is especially useful in the early phase 
after tracer administration. Later on, tracer concentrations in circulation and tissues 
change more slowly, and data can be collected using longer, single (“static”) scans 
of 10 min or longer from the area of interest.  
Before analysis, the data are typically automatically corrected for dead time 
(correction for loss of data before another signal can be detected by the scanner), 
decay (correction accounting for natural decay of the radionuclide after the 
injection), and photon attenuation (correction for photons that do not reach the 
detectors but are absorbed in tissues) (Turkington, 2001).  
To recognize anatomical regions of interest from PET images, the study is 
combined with a computed tomography (CT) or magnetic resonance imagin (MRI) 
scan, or more rarely, a reference image. The CT or MRI data are also required for 
attenuation correction. 
 
Figure 8. Left: A transverse PET/CT image of the thoracic 
region from a [18F]-FDG study. A PET image (upper left) 
and a CT image (middle left) are combined into one (lower 
left) to aid the localization of [18F]-FDG uptake. The brighter 
color indicates a higher tracer uptake in the left ventricular 
myocardial wall in relation to other tissues in the field of 
vision. Up: Combined PET/CT scanner Discovery 690 
(General Electric Medical Systems, Milwaukee, WI) from 
Turku PET Centre. 
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2-deoxy-2-[18F]fluoro-D-glucose ([18F]-FDG) 
The radiotracer [18F]-FDG is widely used in both diagnostics and research. Its 
benefits include a relatively long half-life of fluorine-18 (~110 min) and efficient 
synthesis by nucleophilic fluorination (Hamacher et al., 1986). [18F]-FDG’s 
molecular structure is similar to glucose, with the fluorine-18 having replaced the 
hydroxyl group in the C-2 position, resulting in comparable transportation into 
tissues. After transportation, similarly to glucose, [18F]-FDG is phosphorylated by 
hexokinase into [18F]-FDG-6-phosphate ([18F]-FDG-6-P) (Bessell et al., 1972). 
However, the absence of the 2-hydroxyl group prevents glycolysis (Bachelard, 1971; 
Horton et al., 1973) and hinders incorporation into glycogen (Bender et al., 2001; 
Iozzo et al., 2007), resulting in promoted trapping of the molecule inside the cells 
until the radioactive fluorine is decayed into stable oxygen-18. This enables quite 
straightforward modeling of tissue [18F]-FDG uptake during the first 30 to 120 min 
after injection (Phelps et al., 1979; Huang et al., 1980). 
Modeling tissue [18F]-FDG metabolism 
Quantitative analysis of tissue [18F]-FDG uptake is performed by comparing the 
accumulation of the tracer in tissues to tracer availability in circulation during the 
scan. Tissue activity is determined from PET images, while plasma activity over time 
(“input function”) can be derived from plasma samples collected during the scan, 
from PET data, or from a combination of the two. The most refined method to 
measure [18F]-FDG uptake is the graphical analysis, which is based on a 
compartmental model. 
The commonly used three-compartmental model consists of [18F]-FDG in 
plasma and tissue, the phosphorylated [18F]-FDG-P, and the constant rates between 
these compartments (Figure 9) (Sokoloff et al., 1977). K1 and k2 represent rates of 
transportation across the cell membrane, while k3 represents phosphorylation and k4 
dephosphorylation of [18F]-FDG. k4 is considered insignificant during the early 
phase of the scan and is further suppressed by insulin stimulation (Iozzo et al., 2017). 
Figure 9. Three-compartmental model of [18F]-FDG kinetics, with Ks representing rates of 
transportation (K1 and k2), phosphorylation (k3), and dephosphorylation (k4). Modified from Ratib et 
al. (1982) with permission from publisher © SNMMI. 
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In the first ~60 min after [18F]-FDG injection, the dephosphorylation rate (k4) is 
assumed to near 0, after which it remains relatively low for another 60 min. During 
this time, an estimated total rate constant (Ki), representing both transportation and 
phosphorylation, can be calculated as the product of [18F]-FDG phosphorylation (k3) 
and [18F]-FDG distribution volume (Phelps et al., 1979; Ratib et al., 1982): 
𝐾𝐾𝑖𝑖 = 𝑘𝑘3  ×  
𝐾𝐾1
𝑘𝑘2 + 𝑘𝑘3
  
This model was developed further into graphical analysis (Gjedde, 1982; Patlak et 
al., 1983). It was later generalized by Patlak and Blasberg, who suggested that as 
long as there is one irreversible compartment in the target tissue (here the 
phosphorylated [18F]-FDG-P), and assuming that the tracer concentration in other, 
reversible compartments is stable and in equilibrium with plasma concentrations, the 
tracer concentration in tissues divided by plasma concentration represents the overall 
tissue uptake rate (Patlak & Blasberg, 1985). When a minimum of three 
measurement points of tissue activity can be fitted linearly, the plot yields a slope 
(Ki, 1/min) that represents how much of the available tracer has accumulated in the 
tissue, and this so-called Patlak plot can be described with the following equation:  
𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡(𝑇𝑇)
𝑆𝑆𝑝𝑝𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝(𝑇𝑇)
= 𝐾𝐾𝑖𝑖  ×  
∫ 𝑆𝑆𝑝𝑝𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝(𝑡𝑡)𝑑𝑑𝑡𝑡
𝑇𝑇
0
𝑆𝑆𝑝𝑝𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝(𝑇𝑇)
 +  𝐺𝐺𝐼𝐼𝑡𝑡 
where tissue concentration (Ctissue) in relation to tracer availability (plasma 
concentration, Cplasma) during a frame is calculated by multiplying Ki (the constant 
for net tracer influx rate into the tissue) by integral of plasma concentration from 
injection until the middle of the selected frame, divided by plasma concentration 
during the frame, and by adding the intercept (Int) of the slope with the y-axis. 
Calculating Ki is also visualized in Figure 10. 
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Figure 10. Mean tracer concentration in tissue during three short frames (Ctissue, with actual tissue 
concentration depicted by a dashed line) is divided by plasma tracer concentration (Cplasma) to 
calculate y-axis values. Values for the x-axis come from dividing the integral of Cplasma with Cplasma. 
The three measurement points ideally fit linearly and produce a slope representing the tissue net 
influx rate of the tracer (Based on Oikonen, 2019). 
The same plot cannot be applied for static scans, as they only produce one measured 
value, nor when the assumption of linearly increasing accumulation of activity in the 
tissue is not fulfilled. For these studies, the [18F]-FDG fractional uptake rate (FUR, 
1/min) can be calculated by dividing tissue activity (Ctissue) by the integral of plasma 
activity from injection until the middle of the selected frame (Camici et al., 1986): 
𝐹𝐹𝑈𝑈𝐺𝐺 =  
𝑆𝑆𝑡𝑡𝑖𝑖𝑡𝑡𝑡𝑡𝑡𝑡𝑡𝑡
∫ 𝑆𝑆𝑝𝑝𝑝𝑝𝑝𝑝𝑡𝑡𝑝𝑝𝑝𝑝(𝑡𝑡)𝑑𝑑𝑡𝑡
𝑇𝑇
0
 
The formula is an estimate of the Patlak-Gjedde plot, and it is based on the 
assumption that after a longer period of time since injection, the distribution volume 
of [18F]-FDG is no longer important (Thie, 1995). Concluding on mathematical 
simulations, FUR can be considered an adequate estimate, yielding values <5% 
higher than the true Ki after 70 min from injection, as used in the studies included in 
this thesis (Oikonen, 2018).  
To convert tissue [18F]-FDG uptake into GU, differences in the transportation 
and phosphorylation rates of glucose and [18F]-FDG, as well as the prevailing blood 
glucose concentration during the scan, must be taken into account. The method is 
described in detail in Chapter 4.2.6. 
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2.4.4 Magnetic resonance spectroscopy 
The magnetic resonance spectroscopy (MRS) technique utilizes signals acquired 
from hydrogen, carbon, nitrogen, and phosphorus, and it offers a possibility to 
investigate tissue concentrations of, for example, glucose, lactate, and glycogen, as 
well as tissue lipid content. Compared to PET, it offers the ability to study more rapid 
changes in metabolite concentrations; however, it is still somewhat limited by a 
poorer signal-to-noise ratio, especially in tissues with a higher lipid content (Befroy 
& Shulman, 2011). These issues can be addressed by administering 13C-enriched 
substrates, such as glucose, lactate, and acetate, when assessing glucose metabolism 
(Lanz et al., 2013).  
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3 Aims 
This thesis aims to add to the current knowledge on insulin signaling in humans. It 
details how a genetic variant predominantly affecting skeletal muscle can affect body 
insulin-stimulated glucose metabolism and whether GU into peripheral tissues can 
be affected by central insulin stimulation or SGLT2 inhibition facilitating PET. 
 
The specific aims of this thesis are as follows: 
 To evaluate a) how a genetic variant known to increase the risk of T2D 
affects tissue insulin sensitivity before the onset of diabetes and b) 
whether PET is an appropriate tool to estimate the effects of rare variants 
on glucose metabolism (Study I). 
 To assess whether central hyperinsulinemia can regulate insulin-
stimulated glucose metabolism in peripheral tissues (Study II). 
 To study the presumed effects of SGLT2 inhibitor dapagliflozin on 
insulin sensitivity in different tissues in subjects with T2D using PET 
(Study III). 
 To investigate whether SGLT2 inhibitor dapagliflozin can reduce liver 
and body fat content after 8 weeks of treatment in subjects with T2D 
facilitating MRI (Study III). 
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4 Materials and Methods 
A total of 86 subjects volunteered for the three sub-studies. All study visits including 
imaging studies were performed at the Turku PET Centre, Turku University 
Hospital. The study protocols were approved by the local Ethics Committee of the 
Hospital District of Southwest Finland (Studies I–III) and the Finnish Medicines 
Agency Fimea (Studies II–III). All subjects provided their written informed consent 
before participation, and the studies were conducted according to the Declaration of 
Helsinki. 
4.1 Study designs and subjects 
4.1.1 Study I: Impact of rare genetic variant p.P50T/AKT2 on 
tissue-specific insulin sensitivity  
Study design 
All the subjects (N = 45) had one study visit to the Turku PET Centre, including a 
[18F]-FDG PET/CT scan during the hyperinsulinemic-euglycemic clamp. The 
subjects arrived at Turku the night before the visit, and the clamp commenced in the 
morning, after an overnight fast of 10–12 hours. The subjects were instructed not to 
take any medications on the morning before the studies.  
Study subjects  
Twenty male subjects (19 heterozygous, 1 homozygous) carrying the variant 
p.P50T/AKT2 and 25 age- and BMI-matched male controls were recruited from the 
Metabolic Syndrome in Men (METSIM) cohort based in Kuopio (Stančáková et al., 
2009; Laakso et al., 2017), and they were pre-screened by the local study team. 
Inclusion criteria for enrolment were age 50–75 years and BMI 20–40 kg/m2; the 
characteristics of both study groups are presented in Table 1. Subjects with diabetes 
(diagnosed previously or in a recent OGTT), as well as subjects with any other 
chronic disease (e.g. thyroid disorder) or medication affecting glucose metabolism 
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(e.g. beta blockers, steroids), were excluded from the study. Furthermore, previously 
unreported data from the METSIM population were used to calculate the sample 
size, with the mean difference in M-values between groups being 25 (SD 18.9) 
µmol/kg/min, with 95% power at a significance level of 5%. 
Table 1. Characteristics of the two study groups. Data are reported as mean ± SD. Modified from 
Original Publication I (Latva-Rasku et al., 2018). 
Variable Carriers (N = 20) Controls (N = 25) P value 
Age (years) 62 ± 6.3 64 ± 4.8 0.23 
BMI (km/m2) 28.7 ± 3.4 28.1 ± 3.4 0.60 
Waist (cm) 100 ± 9 101 ± 9 0.88 
Body fat percentage (%) 28 ± 7 29 ± 7 0.60 
Fasting plasma glucose (mmol/L) 6.1 ± 0.3 6.0 ± 0.5 0.28 
Fasting plasma insulin (mU/L) 18 ± 10 9 ± 6 0.003 
4.1.2 Study II: Effects of intranasal insulin on tissue glucose 
uptake 
Study design 
The study comprised of three visits: one screening visit and, for the 10 eligible 
subjects recruited for the complete study, two visits with [18F]-FDG PET/CT scans 
during the hyperinsulinemic-euglycemic clamp. The screening visit included an 
inspection of medical history, a physical examination, a measurement of body fat 
percentage, collection of fasting laboratory samples, and a 2-hour, 75-g OGTT. After 
eligibility was confirmed by laboratory results, the first scan visit was scheduled 3 
to 26 days later, and the second scan visit 2 to 20 days after the first scan. Before the 
first scan, the subjects were allocated by block randomization to receiving either 
insulin or placebo nasal sprays first. The study was registered at ClinicalTrials.gov 
(Identifier: NCT02933645). 
Study subjects 
Ten lean, healthy male subjects were recruited for the study using personal contacts 
and advertisements on the university website. The inclusion criteria were age 20–35 
years, BMI 18.5–25 kg/m2, fasting plasma glucose less than 6.1 mmol/L, and 2-hour 
75-g OGTT glucose values within reference range. The characteristics of the study 
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subjects are presented in Table 2. Reasons for exclusion were any chronic disease or 
medication that could affect glucose metabolism, a history of eating disorders, 
smoking, taking snuff, the use of narcotics, abusive use of alcohol, and previous 
participation in a PET study. Three subjects did not meet the inclusion or exclusion 
criteria and were not included in the following study visits. The sample size was 
calculated to detect a 21.9% placebo-corrected change in GIR with 95% power at a 
significance level of 5%, based on then unpublished results by collaborators in 
Tübingen. 
Table 2. Characteristics of the study subjects. Modified from Original Publication II. 
Variable Mean ± SD Range 
Age (years) 24 ± 2.6 20–28 
BMI (km/m2) 23.5 ± 2.0 20.0–25.6 
Waist (cm) 82 ± 6 74–92 
Hip (cm) 97 ± 5 90–106 
Waist-hip ratio 0.84 ± 0.04 0.80–0.91 
Body fat percentage (%) 16.5 ± 3.7 9.7–20.3 
Fasting plasma glucose (mmol/L) 5.2 ± 0.6 3.7–5.8 
Fasting plasma insulin (mU/L) 5 ± 3 1–10 
Matsuda-ISI 9.4 ± 6.9 3.5–27.2 
4.1.3 Study III: Effects of SGLT2 inhibitor dapagliflozin on 
insulin resistance, liver fat content, and body fat mass 
after 8 weeks of treatment 
Study design 
The study flowchart is presented in Figure 11. All volunteers first underwent a 
screening visit at the Turku PET Centre (N = 51) or at a satellite site in Jyväskylä (N 
= 4). Their eligibility for the study was monitored during this visit by investigating 
their medical history and medications, performing a physical examination, and 
collecting fasting laboratory samples.  
For the 32 eligible subjects, [18F]-FDG PET/CT and MRI scans were performed 
at Visits 2 and 4 at Turku PET Centre, while treatment follow-up (Visit 3) and 
telephone follow-up (Visit 5) were organized by the recruiting site. The [18F]-FDG 
PET/CT scans during the hyperinsulinemic-euglycemic clamp were performed after 
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an overnight fast of 10–12 hours, and the 
subjects were instructed not to take 
metformin, DPP-IV inhibitors, or any 
concomitant medications known to affect 
glucose metabolism before the end of the PET 
scan. On Visits 3 and 4, they were also 
instructed not to take the study medication on 
the morning of the visit. The MRI scans were 
performed after a minimum fast of 4 hours, 
with no restrictions on taking medications, 
and at the same time of the day on both visits. 
The subjects were randomized on Visit 2 
to receive either 10 mg of dapagliflozin 
(Forxiga®) or the placebo (both provided by 
AstraZeneca AB, Mölndal, Sweden) in the 
morning, starting from the day following the 
scans. Randomization was performed 1:1 in 
balanced blocks in two strata. One subject in 
the dapagliflozin group was discontinued 
from the study on Visit 2 before study drug 
administration due to elevated liver enzymes. 
Compliance was evaluated based on the 
amount of returned study medicine on Visit 4. 
The study was registered at 
ClinicalTrials.gov (Identifier: 
NCT02426541). 
Study subjects 
Fifty-five volunteers, who were initially recruited from outpatient clinics, from 
patient databases, or by advertisements in newspapers and on the hospital website, 
were screened. Of them, 32 subjects with previously diagnosed but inadequately 
controlled (defined as HbA1c 6.5–10.5% or 48–91 mmol/L) T2D were included in 
the study. The enrolled subjects also fulfilled the following main inclusion criteria: 
age 35–70 years, BMI less than 40 km/m2; minimum of 6 months from diagnosis of 
T2D; and ongoing, stable medication with metformin, dipeptidyl peptidase 4 
inhibitor (DPP-4 inhibitor), or a combination of the two. The baseline characteristics 
of both groups are presented in Table 3. The following exclusion criteria were 
applied: any other diabetes medication or use of medication possibly affecting 
glucose metabolism, untreated hypertension at screening visit (>160/100 mmHg), 
Figure 11. Study flowchart. 
Modified from Original Publication 
III (Latva-Rasku et al., 2019). 
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unstable coronary syndrome, symptomatic cardiac failure, renal impairment 
(creatinine clearance less than 60 mL/min using the Cockcroft-Gault equation), and 
significantly increased liver enzyme levels (Alanine aminotransferase [ALT] or 
aspartate transaminase [AST] >3 times upper limit of normal, or total bilirubin >34.2 
µmol/L). The sample size was set to detect a 25% change in skeletal muscle GU, 
with approximately 90% power at a significance level of 5%.  
Table 3. Characteristics of the two treatment arms. Data are reported as mean ± SD. Modified from 
Original Publication III (Latva-Rasku et al., 2019). 
Variable Dapagliflozin 10 mg 
(N = 15) 
Placebo                (N 
= 16) 
P value 
Sex (m/f) 13/2 12/4  
Age (years) 60 ± 9.9 61 ± 5.7 0.74 
BMI (km/m2) 32.1 ± 3.9 31.7 ± 5.0 0.81 
Waist (cm) 111 ± 9 108 ± 11 0.48 
GHbA1c (%) 7.0 ± 0.6 6.9 ± 0.5 0.84 
HbA1c (mmol/L) 53 ± 7 51 ± 6 0.38 
Fasting plasma glucose (mmol/L) 9.5 ± 1.9 8.8 ± 1.7 0.31 
Fasting plasma insulin (mU/L) 20 ± 11 19 ± 12 0.79 
Diabetes duration (years) 8.5 ± 2.7 6.4 ± 4.5 0.13 
 
4.2 Methods 
4.2.1 Preparing for the PET scans with hyperinsulinemic-
euglycemic clamp 
In the current studies, the hyperinsulinemic-euglycemic clamp was applied together 
with PET imaging to measure both whole-body and tissue-specific insulin sensitivity 
(Nuutila et al., 1992). Two cannulas were initially inserted in opposite forearms: one 
for the [18F]-FDG injection and infusion of glucose and insulin, and another one for 
the collection of blood samples. The arm used for sampling was warmed using hot 
water bottles to acquire arterialized blood. During the clamp in Studies I and III, i.v. 
fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) was 
administered at a steady rate of 40 mU/m2/min (corresponding to 1 mU/kg/min) after 
7 min of priming with higher doses. Euglycemia (plasma glucose level 5.0 ± 0.5 
mmol/L) was sustained by varying the infusion rate of 20% glucose solution based 
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on plasma glucose measurements performed every 5–10 min. The clamp was 
continued until the end of the PET scans. 
Plasma insulin was measured at fasting and every 30 min throughout the clamp to 
ensure adequate insulin levels during the study. Furthermore, serum FFAs were 
measured at fasting and every 60 min to investigate insulin’s effect on lipolysis. 
Whole-body GU (M-value; DeFronzo et al., 1979) was reported as an average of 
three to four 20-min periods during steady euglycemia. 
Modified low-dose clamp (Study II) 
In Study II, the clamp procedure was modified to a lower dose of 0.25 mU/kg/min 
on both visits. This was done to hinder the strong effect of systemic insulin that could 
both saturate central IRs and surpass the possible effects of central regulation on 
peripheral GU, or (Heni et al., 2014; Heni et al., 2017).  
Nasal insulin and placebo sprays (Study II) 
Nasal sprays containing fast-acting human insulin (Actrapid, Novo Nordisk A/S, 
Bagsvaerd, Denmark) or a placebo (Insulin Diluting Medium for Novorapid and 
Levemir, Novo Nordisk A/S, Bagsvaerd, Denmark) were manufactured by the local 
hospital pharmacy as described by Heni et al. (2014). The sprays were given in a 
randomized order in a single-blinded fashion. 
The nasal insulin sprays were administered 30 (SD 4) min after the start of the 
clamp, with a total of 160 IU inhaled as eight puffs in each nostril over 4 min. The 
same spraying protocol was applied with the placebo, beginning at 29 (SD 4) min, 
with an additional 2.5 mU/kg of i.v. insulin over 15 min started simultaneously to 
mimic the spillover of nasal insulin into systemic circulation (Plomgaard et al., 2019) 
(Figure 13B). 
Correction for urinary glucose loss (Study III) 
The amount of glucose lost to urine during a clamp is usually negligible, but for the 
subjects on dapagliflozin (N = 15), the loss had to be subtracted from the original M-
value for the calculation to better represent whole-body insulin sensitivity. Rates of 
urinary loss of glucose and [18F]-FDG were significantly correlated (r = 0.74, p = 
0.038) in eight subjects with both measurements in the dapagliflozin group (Figure 
12): 
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Figure 12. Correlation 
between clearances of 
glucose and [18F]-FDG 
were significantly 
correlated in the 
dapagliflozin group 
after 8 weeks of 
treatment (N = 8). 
From Original 
Publication III (Latva-
Rasku et al., 2019). 
 
The following linear equation model was hence applied to estimate the rate of 
glucose excretion into urine in the seven other subjects receiving dapagliflozin: 
𝑈𝑈𝑆𝑆𝑔𝑔𝑝𝑝𝑡𝑡𝑔𝑔𝑔𝑔𝑡𝑡𝑡𝑡  =  −13.47 +  1.92 × 𝑈𝑈𝑆𝑆𝐹𝐹𝐹𝐹𝐹𝐹 
where UCglucose is the rate of urinary glucose loss (µmol/min), and UCFDG is the rate 
of urinary loss of [18F]-FDG (µmol/min). To combine the rate into the M-value 
calculation, it was divided by subject weight. 
4.2.2 Conducting of PET scans during clamp 
After reaching steady euglycemia, the subjects were transferred to a PET/CT scanner 
(Discovery 690, General Electric Medical Systems, Milwaukee, WI) and instructed 
to lay in supine position. After an initial scout CT to aid in selecting scan locations, 
the subjects were injected with a single bolus of [18F]-FDG, and the PET scan was 
started right after (Figure 13A). The mean interval between the start of the clamp 
and injection was 69 (SD 15) min in Study I and 75 (SD 15) min in Study III, while 
[18F]-FDG doses were 152 (SD 10) megabecquerel (MBq) and 155 (SD 8) MBq, 
respectively. In Study II, the tracer administration was fixed to the start of nasal 
sprays, and the interval was 40 (SD 6) min after insulin sprays and 39 (SD 9) min 
after placebo sprays (Figure 13B). 
All the different areas were scanned sequentially in a single session and included 
dynamic scans of the thoracic area (for 40 min, 4 x 15 sec, 6 x 20 sec, 2 x 60 sec, 2 
x 150 sec, 6 x 300 sec); upper abdomen (15 min, 3 x 300 sec); and thighs (15 min, 3 
x 300 sec), followed by static scans of the neck (10 min) and the brain (10 min, only 
Studies I and II) (Figure 13A). The emission scans were preceded by short low-dose 
or ultra-low-dose CT scans from the same region. Finally, the plasma samples used 
to determine blood radioactivity were collected at 5, 10, 20, 30, 40, 47.5, 62.5, 75, 
and 85 min after injection, and the amount of tracer lost to urine was measured from 
a urine sample collected at the end of the scan. 
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Figure 13. A. Timeline of study procedures for Studies I and III. The PET scan was preceded by a 
whole-body scout CT and followed by a low-dose or ultra-low-dose CT scan (gray bars) of each 
area before the PET scan. Brain scans were performed only in Studies I and II. B. Timeline of Study 
II, in which either a total of 160 IU of intranasal insulin (INI) as eight puffs in each nostril over 4 min 
or additional i.v. insulin over 15 min was administered before the scan. The scan was performed 
identically to the one detailed in Figure 13A. 
4.2.3 Brown adipose tissue radiodensity 
BAT radiodensity measured from CT images as Hounsfield units (HUs) can be used 
as an indicator of tissue activity, with a lower HU correlating with increased blood 
flow to the tissue or thermogenesis due to consumed lipid storages (U Din et al., 
2017). In Study II, BAT radiodensity was measured by drawing ROIs manually to 
the supraclavicular depots, excluding voxels that were not within the range of AT 
density (-250 to -50 HU), as described by U Din et al. (2017). 
4.2.4 Magnetic resoncance imaging studies (Study III) 
Whole-body MRI was performed in Study III using the 3T MRI part and an 
integrated body coil of a PET-MR scanner (Philips Ingenuity TF, Philips Healthcare, 
Cleveland, OH). During the scan, subjects laid in supine position, with arms above 
the head when feasible, and they were instructed to exhale and hold their breath 
during imaging of the thoracic area and abdomen. First, a T1-weighted fat-
suppressed single-echo sequence was used to measure the liver volume, followed by 
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an assessment of the liver proton density fat fraction (PDFF%) (Reeder et al., 2012) 
and whole-body composition by a multi-echo water-fat separation method based on 
chemical shift (Dixon, 1984). 
The analyses of the MRI studies were performed by Antaros Medical AB 
(Mölndal, Sweden). Liver volume was measured using a semiautomated 
segmentation tool in SmartPaint software (version 1.0), developed at the Centre for 
Image Analysis and the Department of Radiology, Oncology and Radiation 
Sciences, Uppsala University, Uppsala, Sweden) (Malmberg et al., 2017). 
Furthermore, analysis of the PDFF% was performed on the whole liver, excluding 
tissue borders, using MATLAB (version 9.1, MathWorks, Natick, MA) as described 
by Berglund and Kullberg (2012), with minor adjustments, and reported as the 
median PDFF%. From the whole-body scan, the volumes of subcutaneous and 
visceral AT were determined from the region between the liver dome and femoral 
heads, and they were assessed using an automated segmentation algorithm (Kullberg 
et al., 2009).  
4.2.5 Anthropometric measurements 
The height and weight of the subjects were measured on-site using the equipment 
provided, with the weight measured in the morning in light hospital clothing after 
urinating. Waist circumference was measured from midway between the top of the 
hip bones and the lowest ribs, and hip circumference was measured around the 
largest part of the hips with the subjects standing up, exhaling slowly, and relaxing 
their muscles. In Study II, body fat percentage was measured using bioimpedance 
(Omron BF400 [MBF-400-E], Omron Healthcare Co Ltd, Kyoto, Japan). Moreover, 
blood pressure was measured in supine position after a minimum of 2 min rest with 
the cuff placed around the right upper arm. 
4.2.6 PET data analysis 
Measurement of peripheral tissue glucose uptake 
All the analyses were performed using Carimas Software (version 2.9, developed in 
Turku PET Centre). Volumes of interest (VOIs) were drawn manually to cover the 
quadriceps’ femoris muscles in both legs and the right lobe of the liver, avoiding 
large vessels, waistline subcutaneous AT, intraperitoneal visceral AT, 
supraclavicular depots of brown AT, femoral bone marrow, and several segments of 
the small intestine. Myocardial GU was measured from the walls of the left ventricle 
with the aid of a segmenting tool. Except for the myocardium and liver, the reported 
values are averages of several VOIs. 
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The input, arterial plasma time-activity curve of [18F]-FDG, was determined by 
combining data from the PET data (first 10 min) and arterialized plasma samples. 
Tissue GU (GU, µmol/kg/min) was then calculated using the following formula: 
𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝐺𝐺𝑈𝑈 =  
𝐾𝐾𝑖𝑖  × 𝑝𝑝𝑝𝑝𝑝𝑝𝑇𝑇𝑝𝑝𝑝𝑝 𝑔𝑔𝑝𝑝𝑇𝑇𝑔𝑔𝑔𝑔𝑇𝑇𝑇𝑇
𝑡𝑡𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇𝑇 𝑑𝑑𝑇𝑇𝐼𝐼𝑇𝑇𝑇𝑇𝑡𝑡𝑑𝑑 × 𝐿𝐿𝑆𝑆
 × 1000 
where Ki (or FUR) is the fractional uptake (1/min), plasma glucose is the mean 
glucose level from injection to the end of the scanned area (mmol/L), tissue density 
(kg/L; ICRP, 1975), and lumped constant (LC) is a previously validated constant 
accounting for the differences in transportation and phosphorylation of [18F]-FDG 
and glucose (1.2 for skeletal muscle, 1.0 for liver and myocardium, 1.14 for AT, and 
0.65 for the brain) (Peltoniemi et al., 2000; Iozzo et al., 2007; Bøtker et al., 1997; 
Virtanen et al., 2001; Orava et al., 2011; Honka et al., 2013; Wu et al., 2003). 
Measurement of brain glucose uptake 
Insulin-stimulated GU to the brain was assessed in Studies I and II. Preprocessing 
and analysis of brain PET data was performed using statistical parametric mapping 
(SPM; SPM 12 software [http://www.fil.ion.ucl.ak.uk/spm/]). PET images were first 
spatially normalized using linear and non-linear transformations and smoothing with 
Gaussian kernel (8-mm full width at half maximum) to an in-house [18F]-FDG 
template, similar to the Montreal Neurological Institute standard brain (MNI 
International Consortium for Brain Mapping). Then, FUR was calculated for each 
voxel in the same manner as in other tissues. Both the comparison of FUR in each 
voxel in the whole brain using nonparametric mapping in the SnPM13 toolbox 
(http://warwick.ac.uk/snpm) and the comparison of GU in different anatomical brain 
regions (GU calculated as described in the previous chapter) were performed 
between groups (Study I) and interventions (Study II).  
Measurement of endogenous glucose production 
The mean rate of EGP during the PET scan was calculated as described by Iozzo et 
al. (2006). First, the metabolic clearance rate of [18F]-FDG (MCRFDG, mL/min) was 
calculated by using the following formula: 
𝑀𝑀𝑆𝑆𝐺𝐺𝐹𝐹𝐹𝐹𝐹𝐹 =  
𝑑𝑑𝑔𝑔𝑇𝑇𝑇𝑇𝐹𝐹𝐹𝐹𝐹𝐹 −  𝑇𝑇𝑢𝑢𝑇𝑇𝐼𝐼𝑇𝑇𝐹𝐹𝐹𝐹𝐹𝐹
𝐴𝐴𝑈𝑈𝑆𝑆𝐹𝐹𝐹𝐹𝐹𝐹
  
where doseFDG is the injected dose (in kBq); urineFDG is the amount of tracer lost to 
urine during the entire scan (in kBq); and AUCFDG is the area under curve from 
injection to infinity, estimated from the blood tracer time-concentration curve of 
[18F]-FDG used in tissue GU analyses (kBq/mL*min). 
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Then, the rate of glucose disappearance (Rd, µmol/min/kg) was calculated as 
follows: 
𝐺𝐺𝑑𝑑 =  
𝑀𝑀𝑆𝑆𝐺𝐺𝐹𝐹𝐹𝐹𝐹𝐹 × 𝑝𝑝𝑝𝑝𝑝𝑝𝑇𝑇𝑝𝑝𝑝𝑝 𝑔𝑔𝑝𝑝𝑇𝑇𝑔𝑔𝑔𝑔𝑇𝑇𝑇𝑇
𝑤𝑤𝑇𝑇𝑇𝑇𝑔𝑔ℎ𝑡𝑡
 
where MCRFDG (mL/min) is the metabolic clearance rate, plasma glucose is the 
average level during the entire scan (mmol/L), and weight is the subject’s weight 
(kg). 
 
Finally, EGP (µmol/min/kg) was computed with the following formula: 
𝐸𝐸𝐺𝐺𝐸𝐸 =  𝐺𝐺𝑑𝑑 + 𝑉𝑉𝑔𝑔𝑝𝑝𝑡𝑡𝑔𝑔𝑔𝑔𝑡𝑡𝑡𝑡 × 
∆𝑔𝑔𝑝𝑝𝑡𝑡𝑔𝑔𝑔𝑔𝑡𝑡𝑡𝑡
∆𝑡𝑡𝑖𝑖𝑝𝑝𝑡𝑡
− 𝐺𝐺𝐺𝐺𝐺𝐺 + 𝑇𝑇𝑢𝑢𝑇𝑇𝐼𝐼𝑇𝑇𝑔𝑔𝑝𝑝𝑡𝑡𝑔𝑔𝑔𝑔𝑡𝑡𝑡𝑡 
where Rd is the rate of glucose disappearance (µmol/min/kg), Vglucose is an estimated 
constant for glucose distribution volume (0.19 L/kg), ∆glucose is the change in glucose 
level from injection to the last collected sample (mmol/L), ∆time is the interval 
between injection and the last sample (min), and GIR is the total amount of infused 
glucose during the scan (mg/kg). Moreover, Urineglucose is the excretion rate of 
glucose into urine (µmol/min/kg), which was only applied for subjects on 
dapagliflozin treatment in Study III, as the amount usually equates to 0. 
4.2.7 Biochemical analyses 
During the clamp and scans, plasma glucose was analyzed in duplicates using the 
glucose oxidase method (Analox GM9; Analox Instruments, London, UK). 
Furthermore, plasma and urine activity were analyzed using an automatic gamma 
counter (Wizard1480 3; Wallac, Turku, Finland) at the local PET Centre laboratory. 
In Studies I and III, plasma insulin at fasting and during clamp was measured 
with automated electrochemiluminescence immunoassay, ECLIA (Cobas 8000, 
Roche Diagnostics, Mannheim, Germany) at the Turku University Hospital 
laboratory. In Study II, samples for serum insulin and C-peptide levels during clamp 
were first frozen at -70 ⁰C and later sent to be analyzed by collaborators in Eberhard 
Karls University Tübingen (Tübingen, Germany) with chemiluminescence assays 
(ADVIA Centaur, Siemens, Erlangen, Germany).  
Fasting plasma glucose and urinary glucose (Study III) were assessed by 
enzymatic hexokinase method (Cobas 8000, Roche Diagnostics, Mannheim, 
Germany); blood HbA1c with immunoturbidimetry (Cobas 6000, Roche 
Diagnostics, Mannheim, Germany); and plasma ALT, AST, ALP, and total bilirubin 
with photometric methods (Cobas 8000, Roche Diagnostics, Mannheim, Germany) 
at the Turku University Hospital laboratory on the day of collecting samples. Other 
samples were separated and stored at -70 ⁰C at the Turku PET Centre and analyzed 
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in larger batches. Serum FFAs were analyzed with enzymatic colorimetric method 
assay (NEFA-HR2, ACS-ACOD; Wako Chemicals, Neuss, Germany; Cobas 8000 
c502 Analyzer, Roche Diagnostics), and plasma N-terminal prohormone of brain 
natriuretic peptide (NT-proBNP) and troponine T (TnT) with ECLIA (Cobas 8000, 
Roche Diagnostics, Mannheim, Germany) at the Turku University Hospital 
laboratory. Serum IL-6, MCP-1, and TNF-alpha were assessed with immunoassay 
(Milliplex® MAP Human Cytokine/ Chemokine Magnetic Bead Panel, cat.no. 
HCYTOMAG-60K, EMD Millipore, Billerica, MA, USA) by collaborators at the 
University of Tampere, (Tampere, Finland).  
Before sample collection, tubes for glucagon and active GLP-1 samples were 
prepared by adding KIE/ml of trypsin inhibitor aprotinin (Bayer AG, Leverkusen, 
Germany) and 0.1 mmol/l of DPP-IV-inhibitor Diprotin A (Sigma Aldrich, St Louis, 
MO, USA) to chilled EDTA tubes. Glucagon was analyzed with radioimmunoassay 
(RIA; GL-32K, EMD Millipore, Billerica, MA, USA), active GLP-1 with enzyme-
linked immunosorbent assay (ELISA; EGLP-35K, EMD Millipore, Billerica, MA, 
USA), and FGF-21 with ELISA (Quantikine® Human FGF-21 Immunoassay, R&D 
Systems, Inc., MN, USA) at the Lund University Diabetes Centre (Lund, Sweden). 
4.2.8 Statistical methods 
Study I 
Statistics were performed with IBM SPSS Statistics for Windows software (version 
21.0, IBM Corp, Armonk NY). After correcting data with skewed distributions using 
logarithmic transformation, differences between groups were studied using an 
independent samples t test. Correlations between GUs in different tissues were tested 
using Spearman’s rank correlation and the comparison of correlation coefficients 
between the groups was performed using Fisher’s Z-transformation. The effect of 
outside temperature in the previous 7, 14, and 30 days on BAT GU was tested using 
linear regression. 
Study II 
Analyses for peripheral tissue GU and BAT radiodensity were performed using a 
mixed model for repeated measurements with fixed effects of intervention and 
sequence using SAS software (version 9.4, SAS Institute, Cary, NC). Brain GU was 
analyzed using a paired t-test in SPM12, with p < 0.05 as the cluster-defining 
threshold. Only statistically significant (p < 0.05) clusters after FWE-correction are 
reported. Statistical analyses for serum metabolites were conducted with Rstudio 
(RStudio Inc., Boston MA), with the values first being normalized to the moment of 
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spray application, and then compared between interventions at 60 min and 90 min 
later using the paired Wilcoxon signed rank test.  
Study III 
Statistics were performed by a statistician assigned by AstraZeneca AB (Mölndal, 
Sweden), and all analyses were performed with SAS software (version 9.4, SAS 
Institute Inc., Cary, NC). Changes in anthropometric measurements and laboratory 
results at baseline, Week 4, and at the end of study were analyzed using a mixed 
model for repeated measurements, with the fixed categorical effects of treatment, 
week, treatment-by-week interaction, the randomization strata of sex, and the sex-
by-week interaction, and with fixed covariates of baseline values and baseline 
measurement-by-week interaction. Changes in M-value, tissue GU, liver fat content, 
and body adiposity were analyzed by two-way ANCOVA, set to detect a change at 
a 5% level of significance and applying fixed effects of treatment, sex, and baseline 
value. The baseline NT-proBNP values of subjects with or without hypertension or 
cardiovascular disease were compared using the Wilcoxon sign rank sum test, and 
correlations were tested using Spearman’s rank correlation. 
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5 Results 
5.1 Impact of rare genetic variant p.P50T/AKT2 on 
tissue-specific insulin sensitivity (Study I)  
5.1.1 Carriers of p.P50T/AKT2 show impaired insulin 
sensitivity in most peripheral tissues 
There were no differences in mean plasma glucose levels during the clamp between 
the groups (5.0±0.4 mmol/L in p.P50T/AKT2 carriers vs. 5.0±0.2 mmol/L in non-
carriers, p = 0.53). While fasting levels of serum FFAs did not differ between the 
groups (0.43±0.16 vs. 0.39±0.16 mmol/L, p = 0.36), lipolysis was less suppressed 
after 60 min (65±15% vs. 76±12%, p = 0.01), but not after 120 min (80±12% vs. 
84±19 %, p = 0.10) of clamp. 
Whole-body GU assessed as both the clamp-based M-value and [18F]-FDG-
derived Rd was significantly lower in the carriers of p.P50T/AKT2 versus controls. 
Endogenous glucose production (EGP) also remained at a higher rate in the carriers 
(Figure 14A). 
Glucose uptake (GU) into skeletal muscle was lower in carriers compared to non-
carriers and correlated highly with the M-values (r ≥ 0.90 in both groups). Insulin-
stimulated GU was also lower in the liver of the carriers. Furthermore, there were no 
significant differences in the subcutaneous AT or visceral AT of the carriers vs. non-
carriers, but GU was lower in both the brown AT and femoral bone marrow of the 
p.P50T/AKT2 carriers (Figure 14B). Finally, no differences were observed in the GU 
into myocardium (34.2±16.8 vs. 35.0±12.6 µmol/100 g/min, p = 0.87), duodenum 
(31.9±7.0 vs. 31.7±7.1 µmol/kg/min, p = 0.93), or jejunum (33.2±7.0 vs. 32.4±7.2 
µmol/kg/min, p = 0.71).  
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Figure 14. A. Whole-body insulin sensitivity, measured as M-value or glucose rate of 
disappearance (Rd), was significantly lower in variant carriers, and EGP remained at a higher rate 
during hyperinsulinemia. B. Peripheral insulin-stimulated glucose uptake was significantly lower in 
key metabolic tissues of p.P50T/AKT2 carriers compared to matched controls. Bar height 
represents group mean and whiskers SD. Modified from Original Publication I (Latva-Rasku et al., 
2018). 
 
5.1.2 Increased brain glucose uptake and lost association 
between glucose uptake and endogenous glucose 
production in p.P50T/AKT2 carriers 
Insulin-stimulated GU was globally higher in the brain of p.P50T/AKT2 carriers (p 
= 0.001 in all seven anatomical regions: temporal, parietal, occipital, and frontal 
lobes; midbrain; limbic system; and cerebellum) (Figure 15A). The correlation 
between M-value and mean brain GU was similar in carriers versus non-carriers (ρ 
= -0.56 vs. ρ = -0.66); however, while GU correlated significantly with EGP in the 
non-carriers’ brains, there was no correlation between the two in p.P50T/AKT2 
carriers (p = 0.016 for the difference between groups) (Figure 15B and C). 
 
Figure 15. A. 
Insulin-stimulated 
brain GU was 
globally higher 
across the whole 
brain in variant 
carriers. The colors 
refer to T-scores, 
with brighter areas 
showing statistically 
more significant 
changes. B. and C. 
Brain GU correlated 
with EGP only in the 
control group. 
Modified from 
Original Publication 
I (Latva-Rasku et 
al., 2018). 
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5.2 Effects of intranasal insulin on tissue glucose 
uptake (Study II) 
5.2.1 No change in whole-body insulin sensitivity despite 
higher circulating insulin levels after intranasal insulin 
Plasma glucose and serum fatty acid levels did not differ significantly between the 
interventions (Figure 16A&B). Despite additional infusion of i.v. insulin after 
placebo sprays, serum insulin levels were significantly higher after INI, starting from 
25 min after spray application until the end of study, with the insulin levels being 
higher than fasting values but significantly lower than maximal values during the 
OGTT (Figure 16C). The required GIR seemed to be higher after INI, but the 
difference did not reach statistical significance (maximal effect at 120 min: mean 
difference 0.85 mg/kg/min, 95% CI -0.16, 1.9, p = 0.07) (Figure 16D). 
Figure 16. A. Plasma glucose levels were similar and within euglycemia in both interventions. B. 
Serum total fatty acid levels did not differ between interventions when values were corrected for 
lower initial level on INI visits. C. Serum insulin levels remained significantly elevated after INI. D. 
Difference between glucose infusion rates (GIRs) did not reach statistical significance within the 
period studied. Data are presented as means and SDs, *p<0.05. The gray backgrounds represent 
the 4-min period of spray application at 30 min and the duration of the PET scan. 
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5.2.2 Decreased global brain glucose uptake after intranasal 
insulin 
Cluster-level analysis revealed significantly lower GU after INI in large regions in 
the brain when using a threshold of p < 0.05 (Figure 17), and essentially in the whole 
brain when using a threshold of p < 0.10.  
Figure 17. A. Brain glucose uptake was significantly lower after INI. The FWE-corrected SPM data 
have a threshold at level p < 0.05 and were colored according to voxelwise T-scores, with the green 
shade representing a statistically more significant effect.  
5.2.3 Intranasal insulin shows no effect on peripheral tissue 
glucose uptake or brown adipose tissue radiodensity 
Glucose uptake under mild systemic hyperinsulinemia was not altered by INI in 
skeletal muscle (p = 0.78), the liver (p = 0.56), or waist subcutaneous AT (p = 0.81) 
when including differences in the serum insulin levels at the moment of injection in 
the statistical model (Figure 18). The mean rate of EGP from injection was slightly 
more suppressed after INI, but not to a statistically significant degree (p = 0.15) 
(Figure 18). 
Moreover, BAT GU (p = 0.78, Figure 18B) and radiodensity (-1.1 HU, 95% CI -2.7, 
0.4, p = 0.13) were not significantly affected by INI. One subject was excluded from 
all BAT analyses due to abnormally high GU on the placebo visit, although including 
him had no effect on the interpretation of the result. 
Figure 18. A. and B. INI had no significant effect on GU in skeletal muscle, liver, subcutaneous 
adipose tissue (ScAT), or brown adipose tissue (BAT), and the minor lowering of EGP did not reach 
statistical significance. A. Bar heights represent group mean and whiskers SD. B. Placebo-
corrected mean changes with 95% CI of changes. 
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5.2.4 Unaffected serum markers of lipid metabolism 
Levels of serum total fatty acids, glycerol, apolipoprotein AI or B, and total 
triglycerides or triglycerides in VLDL, low-density lipoprotein (LDL), and high-
density lipoprotein (HDL) normalized to the moment of spray application were not 
affected by INI (Figure 19). 
Figure 19. Serum concentrations of lipid metabolism markers were not affected by INI (black dots 
and lines) compared to placebo (white squares, dashed lines). Total fatty acids (A), glycerol (B), 
apolipoproteins AI (C) and B (D), total triglycerides (TG) (E), and triglycerides in very low -dendity 
lipoproteins (VLDL) (F), low-density lipoproteins (LDL) (G), and high-density lipoproteins (HDL) (H). 
Data are presented as means and SDs.  
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5.3 Effects of SGLT2 inhibitor dapagliflozin on 
insulin resistance, liver fat content and body fat 
mass after 8 weeks of treatment (Study III) 
5.3.1 Improved glycemic control and weight loss by 
dapagliflozin and effects on biomarkers 
Dapagliflozin treatment reduced subjects’ weight and improved their fasting plasma 
glucose and HbA1c values. No changes in fasting plasma insulin, serum FFAs, or β-
hydroxybutyrate were observed. Furthermore, mean glucose values were similar in 
both groups and did not differ between visits. Suppression of lipolysis during 
hyperinsulinemia was not affected by dapagliflozin at 60 or 120 min from the start 
of clamp (Table 4). 
Fibroblast growth factor 21 (FGF21) tended to lower (-111 pg/mL, 95% CI -232, 
9.4, p = 0.07), with the change in liver PDFF% showing a statistically significant 
effect on the decrease (p = 0.01). In addition, levels of IL-6 were decreased by 
dapagliflozin by 1.9 pg/mL (95% CI -3.6, -0.14, p = 0.04). The change correlated 
with the decrease in subcutaneous AT volume (ρ = -0.62, p = 0.02), with the 
treatment effect remaining close to significant despite including the change in 
subcutaneous AT volume in the model. Finally, TNFα levels were not affected by 
dapagliflozin. 
Table 4. Baseline and post-treatment values are reported as mean ± SD. P-values are placebo-
corrected adjusted mean changes from baseline for the dapagliflozin group. FPG: fasting plasma 
glucose, FFA: free fatty acids, GCG: glucagon, β-OHBut: β-hydroxybutyrate, ALT: alanine 
aminotransferase, AST: aspartate aminotransferase, FGF21: fibroblast growth factor 21, TNFα: tumor 
necrosis factor α (pg/mL), and EGP: endogenous glucose production during clamp. Mean glucose is 
the mean value during clamp steady state, and ∆FFAs represent percentage change from fasting after 
60 or 120 min of clamp. Modified from Original Publication III (Latva-Rasku et al., 2019). 
VARIABLE DAPAGLIFLOZIN 10 MG  
(N = 15) 
PLACEBO  
(N = 16) 
P VALUE 
 Baseline At 8 weeks Baseline At 8 weeks  
BMI (kg/m2) 32.1 ± 3.9 31.3 ± 3.7 31.7 ± 5.0 31.8 ± 4.8 <0.0001 
FPG (mmol/L) 9.5 ± 1.9 7.8 ± 0.9 8.7 ± 1.7 9.0 ± 1.5 <0.01 
GHbA1c (%) 7.0 ± 0.6 6.6 ± 0.6 6.8 ± 0.5 6.8 ± 0.4 <0.01 
HbA1c (mmol/L) 53 ± 7 49 ± 7 51 ± 6 51 ± 5  
Fasting insulin (mU/L) 20 ± 11 17 ± 8 19 ± 12 17 ± 8 0.52 
Fasting FFA (mmol/L) 0.64 ± 0.15 0.67 ± 0.14 0.69 ± 0.18 0.66 ± 0.21 0.62 
Fasting GCG (pg/mL) 104.9 ± 15.4 105.8 ± 20.4 111.3 ± 27.6 108.2 ± 26.4 0.68 
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β-OHBut (mmol/L) 0.09 ± 0.05 0.17 ± 0.18 0.12 ± 0.11 0.12 ± 0.09 0.33 
ALT (U/l) 50 ± 21 45 ± 16 38 ± 14 39 ± 15 0.47 
AST (U/l) 30 ± 10 30 ± 10 32 ± 12 31 ± 10 0.92 
FGF21 (pg/mL) 388 ± 315 334 ± 198 293 ± 194 362 ± 272 0.07 
Interleukin-6 (pg/mL) 6.6 ± 8.2 5.8 ± 8.9 3.5 ± 2.4 4.0 ± 4.4 0.04 
TNFα (pg/mL) 4.6 ± 1.4 4.7 ± 1.5 3.6 ± 2.3 3.7 ± 2.2 0.38 
M-value (µmol/m2/min) 6.2 ± 3.3 7.7 ± 3.6 7.8 ± 5.2 8.3 ± 5.1 0.50 
EGP (µmol/kg/min) 7.6 ± 4.4 7.0 ± 4.2 9.4 ± 3.9 7.8 ± 4.0 1.0 
Mean glucose (mmol/L) 5.4 ± 0.4 5.1 ± 0.2 5.5 ± 0.6 5.3 ± 0.6 0.18 
∆FFA 0 to 60 min (%) -58 ± 13 -59 ± 15 -60 ± 14 -61 ± 14  0.71 
∆FFA 0 to 120 min (%) -71 ± 10 -75 ± 11 -71 ± 13 -70 ± 15  0.35 
5.3.2 Glucose uptake not improved by dapagliflozin 
The baseline M-value was low in both groups (Table 4) and was not improved by 
dapagliflozin compared to the placebo (p = 0.90) (Figure 20). The rate of EGP during 
clamp was similar in both groups (Table 4) and was not changed by dapagliflozin (p 
= 1.0) (Figure 20). 
Furthermore, dapagliflozin had no effect on tissue-specific insulin-stimulated 
GU in skeletal muscle (p = 1.0); the liver (p = 0.53); visceral adipose tissue, 
subcutaneous adipose tissue, or BAT (p = 0.71; p = 0.19; p = 0.65, respectively), nor 
on left ventricular myocardial GU (p = 0.46) (Figure 20). However, the small 
changes in the M-value and skeletal muscle GU correlated in the dapagliflozin group 
(ρ = 0.64, p = 0.01) 
Figure 20. Dapagliflozin had no significant effect on whole-body insulin sensitivity, reported as M-
value, on EGP, or on tissue-specific insulin-stimulated glucose uptake. Data are presented as 
placebo-corrected mean changes with 95% CI. Modified from Original Publication III (Latva-Rasku 
et al., 2019). 
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5.3.3 Reduced liver steatosis and body fat mass by 
dapagliflozin 
The baseline liver fat content (PDFF%) was similar between groups: 22% (SD 11) 
in the dapagliflozin group and 21% (SD 9.3) in the placebo group. At the end of 
treatment, there was a significant decrease in both liver PDFF% (placebo-corrected 
mean change -3.7%, 95% CI -6.18, -1.30, p < 0.01) and liver volume (-0.10 L, 95% 
CI -0.19, -0.003, p = 0.04) (Figure 21A). Post-hoc analyses revealed that introducing 
changes in BMI or visceral AT volume in the model had a significant effect on the 
reduction of liver fat (p = 0.02 and p = 0.01, respectively). 
Volumes of visceral AT and abdominal subcutaneous AT were significantly 
reduced by dapagliflozin (placebo-corrected mean changes -0.35 L, 95% CI -0.59, -
0.12, p < 0.01; and -0.28 L, 95% CI -0.52, -0.05, p = 0.02, respectively) (Figure 
21B). Finally, there was no significant change in lean body mass (-1.2 L, 95% CI -
2.8, 0.41, p = 0.14).  
 
Figure 21. A. Change in liver proton density fat fraction (PDFF%) and volume was significant in the 
dapagliflozin group. B. Changes in volumes of visceral and subcutaneous adipose tissue (AT) were 
significantly reduced by 8 weeks of dapagliflozin treatment. Bar height represents mean change in 
each group and whiskers SD. Modified from Original Publication III (Latva-Rasku et al., 2019). 
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6 Discussion 
6.1 A partial loss-of-function variant in AKT2 is 
associated with insulin resistance in several 
insulin-sensitive tissues (Study I) 
The results from this study demonstrate that a low-frequency partial loss-of-function 
variant p.P50T/AKT2 is associated with insulin resistance in several key metabolic 
organs in middle-aged and elderly male subjects without T2D. This is in line with 
previous studies showing that variant carriers presented hyperinsulinemia, 
suggesting impaired insulin sensitivity (Manning et al., 2017). To the authors’ 
knowledge, this is the first time a rare variant has been demonstrated to widely affect 
tissue glucose metabolism in vivo. In addition to key insulin-sensitive tissues, 
skeletal muscle, and liver, the results revealed surprising alterations in several other 
tissues as well. 
Lower whole-body glucose disposal in variant carriers can be explained, at least 
in part, by a) the 36% lower skeletal muscle GU, supported by the central role of 
AKT2 in skeletal muscle glucose GU and glycogen synthesis (Bouzakri et al., 2006) 
and b) the enrichment of the specific isoform in skeletal muscle (Manning et al., 
2017). In addition to the primary defect in insulin signaling, the possible lifetime 
effects of hyperinsulinemia and other manifestations of insulin resistance could have 
further aggravated the situation. 
Manning et al. (2017) also showed, in their in vitro experiments on human 
hepatocytes, that p.P50T/AKT2 is associated with impairment in liver insulin 
signaling, similarly to skeletal muscle. In accordance with this previous report, EGP 
was less suppressed during hyperinsulinemia in variant carriers, indicating hepatic 
insulin resistance. The decrease in liver GU compared to controls can also result 
from lower rates of glycogen synthesis and the associated inefficient glucose 
handling and accumulation of G6P. Both the impaired insulin-stimulated GU and the 
inadequate suppression of EGP by insulin, resulting from impaired AKT2 function, 
have also been displayed in mouse knock-out models (Cho et al., 2001; Garofalo et 
al., 2003; Wan et al., 2013).  
Although insulin-stimulated GU into AT occurs via the AKT2-regulated 
translocation of GLUT4 (George et al., 2004), and while the rates of GU in 
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subcutaneous and visceral WAT were slightly lower in variant carriers compared to 
non-carriers, the difference was not statistically significant. However, a change in 
FFA levels from fasting to 60 min of hyperinsulinemia was more limited in 
p.P50T/AKT2 carriers, suggesting an impaired inhibition of lipolysis. A previous 
report in AKT2 knock-out mice found no effect on lipolysis measured as changes in 
FFA and glycerol levels (Koren et al., 2015), supported by findings that in 
adipocytes, GLUT4 translocation is mediated solely by AKT2 and lipolysis via both 
AKT1 and AKT2 acting on FOXO1 (Gonzalez & McGraw, 2011). Therefore, it is 
possible that in our subjects, the effect was secondary and not a direct result of 
impaired AKT2 function. 
Supraclavicular BAT depots have previously been shown to increase GU in 
response to insulin stimulus more efficiently than WAT (Orava et al., 2011), which 
might explain why we saw a significantly lower GU in the BAT of variant carriers. 
As the used method only allows for an estimation of BAT based on anatomical 
region and radiodensity, it is also possible that the lower GU p.P50T/AKT2 carriers 
had a smaller amount of active BAT, which has previously been shown to be 
associated with obesity and insulin resistance (Orava et al., 2013). Furthermore, in 
other research, mice lacking adipocyte AKT1 and AKT2 had no discernible BAT and 
developed WAT lipodystrophy (Shearin et al., 2016). However, our subjects 
displayed a BMI and fat distribution similar to the controls, opposing several defects 
in AT development by p.P50T/AKT2. 
Adult femoral bone marrow consists mostly of adipocytes, which seem to share 
characteristics of both white and brown adipocytes. In insulin-resistant mice, marrow 
AT demonstrates a decreased expression of genes participating in insulin-mediated 
responses in BAT, but not WAT (Krings et al., 2012), which could explain the 
similar significantly lower GU in femoral bone marrow as seen in BAT. 
Furthermore, femoral marrow GU and BAT GU correlated positively in both groups 
(r ≥ 0.53, p <0.01 in both groups, using log-transformed values). The concept of 
femoral bone marrow AT as insulin-sensitive tissue is also supported by the 
correlation between tissue GU and M-value seen in the current study (r ≥ 0.79, p 
<0.01 in both groups, using log-transformed values) and in a previous report in 
elderly female subjects (Huovinen et al., 2016).  
These two PET studies provide interesting new insights into the role of insulin 
in bone marrow AT metabolism, as research in this regard has been scarce. Insulin 
seems to play an important role in marrow adipocyte expansion, but not development 
(Qiang et al., 2016), and several studies have previously demonstrated that insulin 
resistance, possibly because of sustained hyperinsulinemia, is associated with 
increased marrow AT content (Yu et al., 2016; Ermetici et al., 2018). It can be 
postulated that as insulin resistance is associated with less browning of AT (Bartelt 
& Heeren, 2014), the marrow adipocytes of p.P50T/AKT2 have started to resemble 
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more white than brown adipocytes, resulting in higher intracellular lipid content and 
less stimulation of GU by insulin. Further studies combining in vivo assessments of 
tissue metabolism and the amount of marrow AT, as well as the characterization of 
adipocytes, would be required to draw more detailed conclusions. Nevertheless, the 
amount of yellow bone marrow (~8% of body fat mass in adults; Tencerova et al. 
2019) would not be significant enough to have a large effect on whole-body insulin-
stimulated glucose disposal.  
Contrarily to peripheral tissues, insulin-stimulated brain GU was higher in 
p.P50T/AKT2 carriers. This is in line with previous studies showing that higher brain 
GU during hyperinsulinemic-euglycemic clamps has previously been reported in 
insulin-resistant and morbidly obese subjects, with the rate correlating negatively 
with whole-body insulin sensitivity (Hirvonen et al., 2011; Tuulari et al., 2013; 
Boersma et al., 2018). Determining whether the increase in insulin-stimulated GU 
results from altered central insulin signaling, central inflammation, blood brain 
barrier dysfunction, or some other reason would require further studies directly 
aimed at answering this question. Interestingly, brain GU correlated with EGP only 
in non-carriers. In subjects with impaired insulin sensitivity due to morbid obesity, 
the two values do, however, correlate (Rebelos et al., 2019). This might indicate that 
AKT2 has a distinct role in the function of brain-liver axis, possibly by participating 
in hypothalamic insulin signaling (Obici et al., 2002). 
6.2 Intranasal insulin does not promote peripheral 
glucose uptake, but might reduce brain glucose 
uptake acutely (Study II) 
Based on our results, contrarily to the initial hypothesis, INI does not alter peripheral 
tissue GU or serum markers of lipid metabolism under mild systemic 
hyperinsulinemia in normal-weight, healthy males. However, intriguingly, INI was 
associated with a significant decrease in brain GU when the [18F]-FDG-PET scan 
was started 40 min after spray application. The applied method was planned to detect 
whether the brain, after insulin stimulus, would be able to alter peripheral tissue 
metabolism. While the high dose of insulin administered rapidly straight to CNS 
does not reflect normal physiology, seeing no significant effect in the periphery 
under these pharmacological conditions suggests that brain insulin signaling does 
not orchestrate whole-body metabolism normally either. 
A globally lower cerebral GU after INI in humans has not been reported earlier. 
Interestingly, a recent report using a mouse model found a similar effect when the 
interval between spray application and [18F]-FDG-PET scan was 30 min (Sanguinetti 
et al., 2019). The authors hypothesized that the unphysiologically high CNS insulin 
exposure could result in an inhibition of local insulin action and a lower brain GU, 
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and this can indeed be explained by the downregulation of IR activity by insulin 
itself (Boucher et al., 2014).  
Alternatively, further downstream on the insulin signaling pathway, it can also 
be that the strong insulin stimulus results in increased intracellular G6P, which 
hinders insulin-independent GU regulated by the concentration gradient across cell 
membrane (Whitesell et al., 1995) at the time when [18F]-FDG was administered. 
This would be a possible result from an initial increase in GLUT4-mediated neuronal 
GU (Benomar et al., 2006; Reno et al., 2017) and later saturation of glycogen stores 
in astrocytes (Heni et al., 2011), resulting in excess G6P as the glucose demand in 
the resting state would be low. Furthermore, the conflict between the brain receiving 
no signals of hyperinsulinemia from the periphery and sensing no adjacent decrease 
in glycaemia could also contribute to the finding. As peripheral glucose disposal did 
not increase, the effect should not result from increased glucose disposal in other 
tissues. 
It remains debatable whether the decrease in brain GU could result from limited 
glucose delivery to the brain. This is because while some studies have shown lower 
cerebral blood flow in the hypothalamus and prefrontal cortex after INI in lean 
subjects during fasting (Kullmann et al., 2015, 2017), others have reported no change 
in major cerebral arteries in young, healthy subjects (Akintola et al., 2017). 
At the moment, increased skeletal muscle GU by central insulin stimulus has 
only been demonstrated by one study in mice (Coomans et al., 2011b), while other 
studies have report no effect (Scherer et al., 2011). A significant increase in GIR as 
a sign of improved tissue GU has currently been reported in one human study (Heni 
et al., 2014), but the effect was diminished when the same group accounted for the 
increase in serum insulin levels after INI on the placebo visit (Heni et al., 2017). 
Furthermore, INI has not been shown to affect the whole-body glucose disposal rate 
(Dash et al., 2015; Heni et al., 2017). Two studies attributed the increase in GIR to a 
decrease in EGP (Coomans et al., 2011b; Filippi et al., 2012); therefore, as we did 
not observe changes in EGP, it seems reasonable that the small change in GIR 
remained insignificant.  
Not seeing an effect on EGP is not, however, contradictory to previous reports. 
The method used in our study only enables the estimation of mean EGP from [18F]-
FDG administration until the end of scan (app. 40 to 120 min post sprays), and the 
previous reports have shown the decrease to occur 100 to 120 min (Heni et al., 2017) 
or 3 to 6 hours after spray administration (Dash et al., 2015), or even more delayed, 
as demonstrated in studies activating central KATP channels with diazoxide (Kishore 
et al., 2011, Esterson et al., 2016). Moreover, the systemic insulin levels on both 
interventions might have been high enough to suppress up to 50% of EGP (Rizza et 
al., 1981), leaving the possible additional effect of INI too small to detect in this 
small sample. This would, however, further emphasize the additive, rather than 
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essential role of central regulation in EGP (Perseghin et al., 1997, Edgerton et al., 
2006, Plomgaard et al., 2019). 
The effects of central insulin signaling in inducing BAT thermogenesis via SNS 
activation has also currently been shown only in mice, and under fasting conditions 
(Rahmouni et al., 2014). While Benedict et al. (2011) reported an increase in mean 
postprandial energy expenditure during the 2.5 hours following INI, the difference 
in separate 30 min intervals did not reach statistical significance, and the possible 
spillover of insulin to circulation was not simulated on placebo visits. The different 
timeframe and methodology can also be the reasons we did not observe changes in 
BAT activity. 
Decreased lipolysis and increased lipogenesis following insulin administration 
to the brain, more specifically mediobasal hypothalamus, has been demonstrated in 
mice as a reduced rate of appearance of glycerol during pancreatic clamp (Scherer et 
al., 2011). The transient lowering of glycerol appearance has also been reported in 
humans 0–60 min after INI administration during fasting (Iwen et al., 2014), while 
glycerol levels in circulation and subcutaneous WAT interstitium remained 
unchanged (Gancheva et al., 2015; Iwen et al., 2014). In the current study, no 
significant changes were observed in serum glycerol, although it tended to decrease 
with INI compared to placebo, which is in line with previous studies. Moreover, 
seeing no change in serum triglycerides, apolipoproteins, or fatty acids is in 
agreement with previous studies during fasting (Iwen et al., 2014; Gancheva et al., 
2015) and pancreatic clamp with a constant fed state (Xiao et al., 2017), although 
assessing only total fatty acids instead of free fatty acids limits comparing the current 
results to previous reports. 
6.3 SGLT2 inhibitor dapagliflozin does not improve 
tissue insulin-stimulated glucose uptake, but 
alleviates hepatic steatosis and reduces body 
fat content (Study III) 
The results from this study show that the previously reported ameliorating of insulin 
resistance by SGLT2 inhibitors is not a result of perpetual improvement in insulin-
stimulated GU in peripheral tissues—to some extent in contradiction to previous 
studies lacking the ability to quantify tissue metabolism directly. However, in line 
with several recent reports, dapagliflozin treatment induced a significant decrease in 
liver steatosis and size, as well as in subcutaneous and visceral AT volumes, without 
affecting lean body mass. 
Surprisingly, the observation of no effect on whole-body and tissue-specific 
insulin-stimulated GU and EGP differs from previous reports (Merovci et al., 2014, 
2016; Mudaliar et al., 2014; Daniele et al., 2016; Matsuba et al., 2018). Comparing 
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the results from the current study with previous ones is not, however, completely 
straightforward, as other groups used two- to threefold higher rates of insulin 
infusion and longer clamp durations (Merovci et al., 2014, 2016; Mudaliar et al., 
2014; Daniele et al., 2016; Matsuba et al., 2018). It has been shown that increasing 
the insulin infusion rate first results in an enhanced suppression of EGP, followed by 
increased tissue GU (Rizza et al., 1981), while the slow increase in GIR in response 
to increasing insulin sensitivity often seen in longer hyperinsulinemic clamp studies 
can be attributed to, for example, prolonged fasting, diurnal changes in insulin 
sensitivity, and changes in endogenous insulin production (Swinnen et al., 2008). As 
a consequence, EGP seems to have been less completely suppressed in our study. 
However, this does not affect the fact that we saw no change in tissue-specific GU 
measured from PET data, as the directly quantified results are independent of EGP.  
The improvement in whole-body insulin sensitivity has been considered as a 
proof-of-concept for glucotoxicity—hyperglycemia per se deteriorating insulin 
sensitivity—as SGLT2 inhibition should not have direct effects on major insulin-
sensitive tissues (Merovci et al., 2014; Mudaliar et al., 2014). Others argue that the 
insulin-sensitizing effect of SGLT2 inhibitors results from significantly promoted 
fatty acid oxidation and alleviated lipotoxicity caused by a reduced amount of 
ectopic fat (Ferrannini et al., 2014, 2016; Daniele et al. 2016).  
Indeed, four studies (Ferrannini et al., 2014, 2016; Mudaliar et al., 2014; Daniele 
et al., 2016) have shown a substrate shift from the oxidation of glucose to fatty acids. 
Only Daniele et al. (2016) have currently reported an increase in net glucose disposal 
because of a significant increase in skeletal muscle glycogen synthesis, whereas 
Ferrannini et al. (2016a) demonstrated a decrease in total postprandial glucose 
disposal, possibly resulting from increased lipolysis. 
 The paradoxical increase in EGP reported by Merovci et al. (2014) and 
Ferrannini et al. (2014) — but not by Mudaliar et al. (2014) and Daniele et al. (2016) 
— was hypothesized to result from the body trying to account for the glucose lost to 
urine by increasing the secretion of glucagon. Indeed, in these two studies 
administration of SGLT2 inhibitor, decrease in plasma glucose and responsive 
increases in glucagon and EGP seemed to have a temporal relationship. The lack of 
an effect on EGP in the current study might therefore be associated with no change 
in fasting glucagon levels or in the glucagon/insulin ratio. This can be because, as 
opposed to earlier reports, the study drug in the current study was not administered 
on the day of the measurements, and the increase in glucagon has been shown to 
result from acute glucose-lowering effects of SGLT2 inhibition (Lundkvist et al., 
2019) rather than improved hepatic insulin sensitivity or direct stimulation of α-cells 
(Bonner et al., 2015). Furthermore, the interval of over 24 hours between the last 
dose of study medication and the PET studies can also contribute to the observation 
of no change in glucose disposal or systemic lipolysis, as enhanced lipolysis has also 
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been suggested to occur to compensate for glucose lost to urine (Daniele et al., 2016). 
Therefore, the results from the current study support the view that SGLT2 inhibitors 
might ameliorate insulin resistance via promoting fatty acid mobilization and 
oxidation acutely, while improved glycaemia alone is not sufficient in increasing 
tissue insulin sensitivity. 
Since the planning of the current study, several reports have demonstrated the 
beneficial effects of SGLT2 inhibitors on liver volume and lipid accumulation (Ito 
et al., 2017; Shibuya et al., 2018; Eriksson et al., 2018; Kuchay et al., 2018). 
Similarly to these previous studies, we also found the association between decreased 
liver steatosis and fat volumes significant, with the connection being further 
established by earlier reports (van der Poorten et al., 2008; Musso et al., 2012). The 
reduction has been attributed to the metabolic shift of tissues favoring fatty acid 
oxidation over glucose oxidation, further augmented by glucagon-driven 
glycogenolysis and gluconeogenesis during fasting (Eriksson et al., 2018; Esterline 
et al., 2018).  
The association between the statistical trend towards lower FGF21 by 
dapagliflozin and the change being strongly associated with the decrease in liver fat 
is in line with the report by Eriksson et al. (2018), who found a significant lowering 
of FGF21, and earlier studies showing a correlation between higher FGF21 
concentrations and NAFLD (Giannini et al., 2013). Interestingly, FGF21 can also be 
considered a marker of mitochondrial function and endoplasmic reticulum stress 
(Jiang et al., 2014) and mitochondrial function and hepatic insulin sensitivity 
(Koliaki et al., 2015; Chavez et al., 2009) in patients with hepatic steatosis. 
Surprisingly, the significant decreases in IL-6 and subcutaneous AT volume 
were negatively correlated, although the excrement by the tissue has been estimated 
to account for up to 35% of systemic IL-6 (Mohamed-Ali et al., 1997). IL-6 can also 
serve as an index of insulin sensitivity (Wang et al., 2013); therefore, it seems that 
the change was driven by some other beneficial inflammatory or metabolic effect by 
dapagliflozin. 
Favorable effects of SGLT2 inhibitors on myocardium have been reported 
widely, with consistent results showing reduced LV mass and improved diastolic 
function (Soga et al, 2018; Verma et al., 2019), while effects on myocardial 
metabolism have not been previously published. In the non-ischemic myocardium, 
energy is mostly (50–70%) derived from FA β-oxidation, but also from degradation 
of glucose, lactate, and ketone bodies, depending on substrate availability 
(Lopaschuk et al., 2010). In insulin resistance, FFA uptake has been shown to 
increase, while β-oxidation is impaired, resulting in impaired myocardial function 
(Lopaschuk et al., 2010). Contrarily, GU is largely unaffected (Paternostro et al., 
1996; Utriainen et al., 1998), especially when accounting for changes or differences 
in circulating FFAs. As lipolysis was not significantly affected by dapagliflozin in 
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the current study, it seems reasonable that the ratio of fatty acid to GU (known as the 
Randle cycle) was not altered. 
However, it can be speculated that as both attenuated FA oxidation (Lopaschuk 
et al., 2010) and a shift from fatty acid to ketone utilization (Ferrannini et al., 2016b) 
could explain the advantageous effects of SGLT2 inhibitors on cardiac health, 
favoring these substrates over glucose could have resulted in decreased GU in the 
current study (Lopaschuk et al., 2010). Further studies are required to determine 
whether the change was not observed because of the interval between dapagliflozin 
administration and PET scans or because the effect on myocardial metabolism 
remains minor in comparison to, for example, changes in preload due to decreased 
blood volume also associated with the treatment. 
6.4 Strengths and limitations 
The strength of these studies lies in the established method of combining [18F]-FDG-
PET with clamp protocols, with much experience with this approach at the Turku 
PET Centre, resulting in the ability to create hypotheses that can be addressed with 
the available techniques. The study procedures and analyses performed with the 
researchers blinded to the genotype of the subjects in Study I and to the treatment 
arm in Study III, as well as the subjects being blinded to intervention in Studies II 
and III, increase the reliability of the results. Furthermore, additional analyses 
performed for the first 24 subjects in Study I revealed a high intra- and interobserver 
reliability of the results: Pearson correlations for skeletal muscle GU were 0.99 
between repeated measurements, 0.98 between original values and those reproduced 
by another analyzer, and 0.92 between repeated measurements of liver GU. 
However, the methods used for insulin stimulation and PET imaging both have 
their limitations. First, although the hyperinsulinemic-euglycemic clamp is 
recognized as the golden standard of measuring insulin sensitivity, the sustained high 
circulating insulin levels and converse proportions of peripheral and portal insulin 
concentrations do not represent normal physiology (Radziuk, 2000). Second, and 
similarly, investigating the effects of insulin on brain metabolism and function by 
applying a large dose of INI produces a pharmacological rather than physiological 
effect (Edgerton et al., 2015), but still appears to be the least invasive and best option 
for investigating brain-specific effects in humans in vivo, at least to create hypotheses 
that can be addressed in further studies. 
Third, the PET/CT machine used in the studies has a resolution of ~5 mm, which 
restrains its use in analyzing small VOIs, such as smaller brain regions (e.g. the 
hypothalamus, intestinal walls, BAT, and subcutaneous, and visceral AT) in slender 
subjects. Smaller structures are all also sensitive to spillover of activity signals from 
surrounding tissues and to motion artefacts from breathing. Fourth, while [18F]-FDG 
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can be considered a reliable measure of glucose transport into the cells for the first 
60 to 80 min after injection, the current methodology does not allow for an 
investigation into intracellular glucose traffic, the possible effects on, for example, 
glycogen metabolism thus cannot be directly assessed. In the late scans (in the 
current studies, this applies to the brain data), it is also possible that some release of 
[18F]-FDG from the cells starts to occur, while the rate and, more importantly, 
relevance of the phenomenon can be disputed. 
Fifth, all PET studies include exposure to ionizing radiation because of the PET 
tracers, and the additional CT was used for anatomical reference. Despite the 
technical development of the PET scanners, the adjustment of the CT to ultra-low 
doses (or using MRI for reference), and the use of insulin infusion in our studies 
reducing the radiation burden, a [18F]-FDG can only be performed twice for the same 
subject in order to stay within the limit of 10 mSv set for scientific studies by the 
Finnish Radiation and Nuclear Safety Authority and EU legislation. 
Sixth, given the radiation burden and the price of PET studies, the number of 
subjects in these studies is usually kept as low as possible. Moreover, attempts to 
avoid large between-subject variability might result in recruiting very homogenous 
study groups and poorer generalizability of the results. With regard to female 
subjects of fertile age, not only is the radiation burden limiting their recruitment, but 
the possible confounding effects of menstrual cycle (Yeung et al. 2010) and 
hormonal contraception (Sitruk-Ware & Nath, 2011) on insulin sensitivity must also 
be considered when using small sample sizes. While including only male subjects in 
Studies I and II can be justified based on the experimental settings, the results should 
not be generalized to females without careful consideration. 
6.5 Future aspects 
To elaborate further on the results from the studies in this thesis and answer the 
questions that have arisen, a wide range of options using PET are available. For 
example, the used protocols could be applied to a wider, more diverse population or, 
after slight modifications, be repeated in similar study groups. In addition, a large 
variety of PET ligands enable the targeting of different hypotheses directly. 
Given the small sample sizes, it was mandatory to try to recruit quite a 
homogenous group of study subjects for Studies I and II. Therefore, it would be 
interesting to study the effects seen in these studies on a wider population in the 
future, as both AKT2 function and INI seem to have diverging effects depending on 
the gender and insulin sensitivity of the subjects. For one, studying the effects of 
p.P50T/AKT2 on female subjects or younger variant carriers with the same validated 
methods already used in Study I would be interesting. In an AKT2 knock-out mouse 
model, female mice displayed less dramatic effects on insulin sensitivity than males 
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(Garofalo et al. 2003), whereas in a family with a loss-of-function mutation of the 
AKT2 gene, heterozygous variant carriers demonstrated severe insulin resistance and 
early-onset T2D in three female subjects but no significant effect on the one male 
family member (George et al., 2004). Investigating the changes in tissue insulin 
sensitivity caused by a less dramatic effect (i.e. in female p.P50T/AKT2 carriers) 
could shed some more light on the possible gender-specific entities regulating insulin 
signaling. Moreover, studying younger variant carriers could elucidate the order in 
which inherited insulin resistance starts to affect different tissues, as data especially 
on the brain are scarce.  
Furthermore, as it might be that impaired signaling via the PI3K-AKT pathway, 
or even more specifically AKT2, is the link between metabolic syndrome and 
Alzheimer’s disease (Gabbouj et al., 2019a, 2019b), performing studies on variant 
carriers that would combine the assessment of insulin-stimulated glucose 
metabolism with [18F]-FDG, scans with PET tracers used specifically for 
Alzheimer’s disease ([11C]Pittsburgh Compound B, [18F]florbetapir [18F]florbetaben 
or [18F]flutemetamol [Marcus et al., 2014]), and evaluation of cognitive function 
could establish the association in real patients. In addition, the hypothesis of central 
inflammation being the reason for increased insulin-stimulated GU could be 
confirmed by using PET tracers binding to brain inflammatory cells, such as R-
[11C]PK11195 or [11C]deuterium-l-deprenyl (Janssen et al., 2016). Moreover, 
previous studies have found no weight loss or suppression of appetite in females 
after INI (Hallschmid et al., 2004; Benedict et al., 2008), but a more pronounced 
beneficial effect on working memory (Benedict et al., 2008); it is thus possible that 
INI could also have a more distinct role in enhancing brain metabolism in females. 
Therefore, investigating whether INI affects insulin-stimulated tissue glucose 
metabolism in female subjects could also be of interest. 
Obese subjects have also shown a contrasting response to brain insulin 
stimulation by INI, with little metabolic effects and supposed faulty brain-liver axis 
(Heni et al., 2017; Xiao et al., 2018). Previous studies performed at the Turku PET 
Centre have demonstrated that morbid obesity is associated with increased insulin-
stimulated brain GU (Tuulari et al., 2013), but applying INI could elucidate whether 
this is a direct central insulin effect or a result of faulty peripheral input to the brain. 
Concerning Study II, in addition to recruiting a more diverse study population, 
rescheduling the PET scans could provide more interesting results: Starting the brain 
PET scan soon after nasal spray application would enable documenting dynamic 
changes in brain glucose metabolism. Moreover, skeletal muscle and liver GU could 
be reassessed at a later timepoint (100–120 min from spray application) to detect 
possible later effects. However, the most crucial action to clarify the results from 
Study II concerning brain metabolism would be to use a method allowing dynamic 
measurement of not only GU to the brain, but also the changes in further metabolic 
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pathways, most notably concentrations of glycogen and lactate. While dynamic 
scans and changes in the initial uptake rate can be detected with PET, investigating 
further effects could be more feasible by combining a [13C]-enriched glucose tracer 
with MRS (Lundqvist et al., 2019). Performing studies on brain metabolism in a 
more physiological setting, postprandially or by stimulating pancreatic insulin 
release, could also be of interest, especially when comparing healthy and insulin-
resistant subjects. 
For the dapagliflozin study, administering the study drug on the day of the PET 
studies and possibly using a higher rate of insulin infusion, or even a two-step clamp 
with increased insulin infusion rates and repeated scans, could help to explain the 
differing results in our studies and provide answers to the hypotheses made by others. 
In a yet unpublished study, the effects of dapagliflozin on myocardial metabolism in 
particular were investigated using PET with fatty acid analogue 14(R,S)-[18F]fluoro-
6-thia-heptadecanoic acid ([18F]-FTHA) and ketone [1-11C]acetoacetate (Åkerblom 
et al., 2019), so these results might elucidate whether the hypothesized substrate shift 
or enhancement of fatty acid oxidation actually occurs. Furthermore, in a previous 
study, bariatric surgery resulted in normalization of insulin-stimulated brain GU 
(Tuulari et al., 2013), but the effect of antidiabetic medicines on brain glucose 
metabolism in T2D subjects has not been reported.
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7 Conclusions 
This thesis aimed to clarify the effects of a genetic variant causing primarily skeletal 
muscle insulin resistance (Study I), as well as central insulin stimulation (Study II), 
on tissue insulin-stimulated GU. It also aimed to determine whether SGLT2 inhibitor 
dapagliflozin could serve as a treatment for insulin resistance (Study III).  
In Study I, it was shown that a rare genetic variant causing a partial loss-of 
function of the AKT2 gene not only decreases GU into skeletal muscle, but is also 
associated with signs of lowered insulin sensitivity in all metabolic key organs. This 
was the first time tissue-specific effects of a rare variant have been demonstrated in 
humans in vivo. Therefore, the report also establishes the role of PET in investigating 
possible outcomes of risk-increasing genetic variants in detail. 
In Study II, it was concluded that INI does not have a major effect on peripheral 
insulin-stimulated GU in healthy subjects, with the major glucoregulatory effect of 
central insulin exposure likely being the suppression of hepatic glucose production, 
either directly or via inhibition of WAT lipolysis. Surprisingly, INI did cause a 
significant decrease in brain GU when the PET scan was started 40 min after 
administration. This can be attributed either to methodological causes or to the 
unphysiological setting, but solving this is outside of the scope of the current study. 
In Study III, it was demonstrated that 8 weeks of treatment with SGLT2 inhibitor 
dapagliflozin does not induce a sustained improvement in tissue-specific insulin-
stimulated GU in subjects with T2D. However, it does have beneficial reducing 
effects on liver fat content, liver volume, and subcutaneous and visceral fat volumes. 
Finally, although [18F]-FDG PET has some limitations as a method, it is currently 
the best approach to assessing tissue-specific insulin-stimulated GU in several 
tissues in one setting. The Small Number of subjects in Study II and including only 
male subjects in Studies I and II can be considered limitations. 
In summary, these studies elaborate the roles of impaired peripheral insulin 
signaling, stimulation of central insulin signaling, and alleviated hyperglycemia and 
decreased body adiposity by a short intervention with dapagliflozin in regulating 
whole-body insulin sensitivity. 
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